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Background: Type I interferon (IFN-I) is thought to have a central role in the 
pathogenesis and activity of autoimmune connective tissue disease (CTD). As a 
heterogeneous condition, CTD is often a challenge to manage, which is further made 
difficult by the lack and imprecision in diagnostic tools. IFN has shown promise as 
biomarkers in correlation studies on disease activity in CTD. Real world challenges in 
CTD management could be addressed with a validated IFN biomarker.     
Objectives: (i) to examine the role of IFN biomarkers in the prediction of flares and 
glucocorticoid requirements in SLE; (ii) to examine the use IFN assays in 
distinguishing patients who meet definite CTD classification criteria from a cohort of 
patients labelled as UCTD; and (iii) to examine the relationship between IFN 
biomarkers and patient-reported outcomes in patients At-Risk, with UCTD and with 
established CTD.   
Methods: A prospective study was conducted in a (i) SLE cohort and a (ii) UCTD 
cohort attending routine clinics. Comprehensive clinical assessment focussing on (i) 
disease activity and glucocorticoid requirements, and (ii) classification criteria for SLE, 
SS, IM and SSc, was conducted in conjunction with IFN biomarker sampling. (iii) A 
cross-sectional study of patient-reported outcomes was administered together with 
IFN biomarker sampling in At-Risk, UCTD and established CTD patients attending 
routine clinic.       
Results: (i) High IFN Score A, IFN Score B and Memory B cell tetherin were 
associated with flares and increased glucocorticoid requirements in a cohort of SLE 
patients; (ii) IFN Score A was higher in those who were re-classified into CTD than 
those remained undifferentiated, thus could be used to distinguish between these two 
groups, and patient’s initially labelled as UCTD; (iii) correlation between IFN Scores 
and PROMs varied widely among diagnoses of CTDs, with the strongest correlation 
found in patients with UCTD. 
Conclusion: In this thesis, I have demonstrated several potential uses of IFN assays 
in the monitoring of patients with CTD with respect to prediction of flares and 
glucocorticoid requirements in SLE; the distinguishment of classifiable CTD from 
UCTD; and understanding the relationships between IFN and patient-reported 
outcomes. These findings need validation in a longitudinal cohort to inform their 
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Chapter 1 Introduction 
The autoimmune connective tissue diseases (CTDs) are a group of chronic systemic 
rheumatic diseases that cause significant morbidity and mortality[1, 2]. Systemic lupus 
erythematosus (SLE) is the prototypical CTD, however Systemic sclerosis (SSc), 
Sjögren’s syndrome (SS) and inflammatory myositis (IM) and variants of these 
disorders are included in the concept[2]. While classification criteria have been 
developed to define definite subsets of CTD, no diagnostic criteria have been 
generated for any of the entities within the CTD spectrum[2]. This contributes to 
delays and inaccuracies in the management of the disease. The mean interval 
between onset of symptoms and the diagnosis of SLE has been estimated at 22 
months[3]. Inaccurate diagnosis of SS (e.g. as RA or SLE) is described in up to 34% 
of SS cohorts, and diagnostic delay is frequently reported among patients with SSc 
and IM[4-6]. 
As classification criteria have not been developed, reports of the prevalence and 
incidence of CTD are limited[7]. North America estimates a prevalence of CTD of 
0.27% and describe the incidence as “very low” [8]. Despite this, CTDs represent a 
substantial proportion of hospital admissions and demand higher than average levels 
of healthcare utilisation [8]. The all-cause annual healthcare cost has been estimated 
at £15,000 per person among all individuals with CTD based on US figures[8]. 
Moreover, significant impairments in quality of life, life expectancy and work 
productivity are evident for all subsets of CTD [9, 10]. The estimated ten year survival 
rate for SSc is reported at 60 – 73%, >90% for SLE, 90% for SS, and 73% for the anti-
synthetase syndrome (a subset of IM) [11-13]. High unemployment and absenteeism 
rates of up to 70% accounted to CTD-related illness have been reported in CTD 
cohorts [14].  
Current methods for the diagnosis and monitoring of CTD is mainly indirect and relies 
on a comprehensive assessment aimed matching findings to known clinical 
syndromes [15, 16]. Many patients are incorrectly given a diagnosis of a CTD and 
exposed to toxic medications[17]. Of the limited biomarkers that are currently available 
in the clinical setting, none have universal application within the CTD population [18, 
19]. There is therefore a need to identify biomarkers that can discriminate CTD from 
mimickers to prevent misdiagnosis and delays in treatment.    
Type I interferon (IFN-I) plays a fundamental role in the pathogenesis of SLE, as 
indicated by genetic susceptibility data and lupus-like disease in monogenic 
interferonopathies[20]. It has also been implicated in SSc, SS and IM[21-23]. Since 
IFN-I activity varies between individuals and is associated with disease activity in SLE, 
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it is of interest as a biomarker across the CTD spectrum[20]. Previous work in our 
group showed that IFN assays could predict progression in an At-Risk cohort and 
correlate with lupus flares and features[24, 25]. Therefore investigating the roles of 
interferon in SLE and other CTDs is the theme of this thesis. 
1.1 Thesis hypothesis 
The unifying hypothesis of this thesis is: 
 
The use of interferon biomarkers will aid the prognosis and management of 
autoimmune connective tissue diseases 
1.2 Overview of planned investigations 
Planned investigations to test the unifying and hypotheses for each chapter were 
divided into three Work-Packages (WPs). These are summarised in .  
Figure 1 Planned work of this thesis 
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Chapter 2 Literature Review 
2.1 Nomenclature, classification and diagnostic criteria 
2.1.1 The spectrum of CTD 
Defined CTD entities exist within a spectrum of more heterogeneous entities that lack 
defining clinical features, laboratory, imaging, or other diagnostic tests (Figure 2). In 
other words, defined CTDs, such as SLE, SS, SSc, IM, can be conceived as part of a 
spectrum including mixed CTD (MCTD), overlap CTD (OCTD), undifferentiated CTD 
(UCTD). In terms of the variant forms of CTD, OCTD represents the full expression of 
two or more defined CTDs [26]. MCTD has mixed clinical features and antibodies 
against ribonuclear proteins. UCTD represents antinuclear antibodies (ANA) and 
clinical features of CTDs that do not fulfil criteria for any one disease. UCTDs may 
evolve into a defined syndrome, remain undifferentiated or regress into remission. 
Approximately 50% of patients with an apparent autoimmune rheumatic disease 
cannot be given a specific diagnosis in the first year of observation[27] and nearly 
25% of patients exhibit features of two or more diseases[28]. 
This concept facilitates the definitive diagnosis of CTD while permitting the option of 
evolving, transient or variant forms of disease. However, prior research has usually 
enrolled homogeneous patient populations. 
2.1.2 CTD classification and diagnostic criteria 
Classification criteria are important for research and epidemiological purposes. They 
are standardised definitions that are primarily intended to enable uniform cohorts in 
clinical studies[29]. Classification criteria prioritise the capture of patients who share 
key features of the specific disease, but are not intended to capture all patients 
affected by the condition. They serve the useful purpose of defining (relatively) 
homogeneous cohorts that can be compared across studies and geographic regions, 
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Figure 2. Clinical spectrum of the CTDs. Traditional CTDs (i.e. SLE, SS, SSc and IM) and composite, transient or undefined 










 Figure 2 Phenotype concept of CTD 
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In contrast, diagnostic criteria are broad and must reflect all the possible different 
features and severity of a disease (heterogeneity)[29]. Both the specificity and 
sensitivity of diagnostic criteria need to be high[29]. Consequently, in the case of the 
CTDs, classification criteria will exclude a greater number of true cases than diagnostic 
criteria (greater false negatives), as diagnostic criteria will tend to risk the inclusion of 
patients with “mimicker” conditions so include all actual disease cases (i.e. greater 
false positives)[29]. The strength of diagnostic criteria and classification criteria is 
impacted by contextual factors such as the prevalence and homogeneity of the disease 
in question and the frequency of disease mimickers[29]. Single universal diagnostic 
criteria are usually not possible due to disease variance across different geographic 
areas, race and ethnicities[29]. If adequate internal and external validity for diagnosis is 
demonstrated in a given population, classification criteria could in theory be diagnostic. 
For example, when classification criteria have absolute (100%) sensitivity and 
specificity, classification and diagnostic criteria are synonymous and have the capacity 
to identify every affected individual[30].   
The utility of classification criteria in routine clinical practice is limited. There is a 
propensity within the rheumatology community to defer to classification criteria when 
the diagnosis is uncertain, however this will be to the detriment of some patients who 
will consequently be denied corrective treatment[29]. Given the complexity of the 
phenotype model of CTD, diagnostic criteria will remain out of reach for CTD until a 
more discerning framework is established. Until such a time, the diagnostic process will 
depend on a subjective combination of clinical signs and symptoms, results of available 
tests, the immunological and autoantibody profile, and the knowledge of epidemiology 
of the geographical region[28].   
2.2 The autoimmune connective tissue diseases  
2.2.1 Systemic lupus erythematosus 
Systemic lupus erythematosus is often referred to as the “prototypical CTD.” It is a 
chronic autoimmune disease characterised by an aberrant autoimmune response to 
nuclear antigens that can affect almost any organ or tissue[1]. It is a heterogeneous 
disease with a diverse range of clinical manifestations that has a typical relapsing and 
remitting course over the lifetime. Lupus predominantly affects women of child-bearing 
age (female: male ratio of 9.1) and has a peak incidence of onset between the ages of 
16 and 55 years[2]. The worldwide prevalence of SLE currently ranges from 20 to 150 
cases per 100,000 population, with the highest prevalence reported in North America 
and Puerto Rica, and the highest incidence reported in people of African, Caribbean, 
Hispanic or Asian racial ancestry compared with white Europeans[31]. Increased 
genetic risk burden in these populations and the associated increased tendency for 
autoantibody reactivity may explain the global ethnic and racial variations. Overall, 
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lupus appears to be increasing in worldwide prevalence as the disease gains 
recognition and survival rates improve, alongside chronicity of the condition[32]. The 
current 10-year survival rate of lupus is approximately 97%[12]. 
2.2.1.1 SLE diagnostic and classification criteria 
Diagnostic criteria for lupus are yet to be established. Classification criteria for lupus 
have been developed as a means to identify uniform and comparable groups of 
subjects for research purposes. The most widely used criteria for SLE was developed 
by the American College of Rheumatology (ACR) in 1982 and later revised in 1997 
(ACR-97)[33]. The ACR-97 criteria are a composite of clinical and immunological 
criteria with classification achievable in the presence of 4 of 11 criteria[34, 35]. The 
criteria have undergone various attempts at refinement including a weighing system in 
the Cleveland Clinic version, and new supplemental criteria such as antiphospholipid 
antibodies in the Boston criteria[36], however these changes have failed to generalise 
into the mainstream[37]. The major criticisms of the ACR-97 were that they (1) over-
represented cutaneous lupus with four cutaneous criteria; (2) omitted 
hypocomplementaemia, one of the most important characteristics for SLE; (3) lacked 
validation in an independent cohort and within multiple ethnic groups; and (4) failed to 
receive development contributions from non-rheumatology stakeholders, such as from 
dermatologists or nephrologists[33]. 
The Systemic Lupus International Collaborating Clinics (SLICC) is an international 
group that presented a new set of classification criteria in 2012 (SLICC-12). The criteria 
required four of 17 criteria, including one of 11 clinical criteria and one of six 
immunologic criteria, or biopsy-proven SLE nephritis in the presence of ANA or anti-
dsDNA antibodies (Table 1). SLICC-12 performed with fewer misclassifications (62 vs. 
74, p=0.24) and had a greater sensitivity (97% vs. 83*, p<0.0001) but less specificity 
(84% vs. 96%, p<0.0001) compared to ACR-97 within validation cohorts[38]. A 2018 
systematic review concluded that the performance of SLICC-12 was best for adult SLE 
whilst ACR-97 was best for juvenile SLE[39]. In adult SLE (nine studies: 5236 patients, 
1313 controls) SLICC-12 had a high sensitivity (94.6% vs. 89.6%) and similar 
specificity (95.5% vs. 98.1%) compared to ACR-97. For juvenile SLE (four studies: 568 
patients, 339 controls), SLICC-12 demonstrated higher sensitivity (99.9% vs 84.3%) 
compared to ACR-97, but much lower specificity (82.0% vs. 94.1%) and therefore 
presented a higher risk of false positives (Table 1). 
2.2.1.2 SLE pathogenesis 
The current model of lupus pathogenesis is based on the sequential breakdown of self-
tolerance in genetically pre-disposed individuals due to environmental influences, 
leading to activation of the innate and adaptive immune systems, and critically, the 
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production of antibodies to nuclear material [1]. In rare cases SLE may be associated 
with the deficiency of a single gene (i.e. the C1q and C4 complement components) but 
in most cases the disease is the result of combined effects of variants in a large 
number of loci[32].  
Table 1 The Classification of SLE: ACR-97 and SLICC-12 criteria 
ACR-97 SLICC-12 
Four of the 11 criteria are needed for 
the classification of SLE 
Four of 17 criteria, including one of 11 clinical 
criteria and one of 6 immunologic criteria 
OR biopsy-proven SLE nephritis with ANA 
Clinical criteria Clinical criteria 
1. Malar rash 1. Acute cutaneous lupus OR subacute 
cutaneous lupus 
2. Discoid rash 2. Chronic cutaneous lupus 
3. Photosensitivity 
4. Oral ulcers 3. Oral ulcers 
 4. Non-scarring alopecia  
5. Non-erosive Arthritis 5. Synovitis OR tenderness in >1 joint and > 
30 min of morning stiffness 
6. Pleuritis or pericarditis  6. Serositis 
7. Renal Disorder 7. Renal 
8. Neurologic Disorder  8. Neurologic 
9. Haematologic Disorder 9. Haemolytic anaemia 
10. Leukopaenia OR lymphopenia  
11. Thrombocytopaenia 
Immunologic criteria Immunologic criteria 
10. Positive ANA  2. Anti-dsDNA antibody  
3. Anti-Sm 
4. Antiphospholipid antibody  
5. Low complement 
6. Direct Coombs’ test  
Table 1. SLE classification criteria. 
2.2.1.3 SLE genetic factors and immune pathophysiology 
Most single-nucleotide polymorphisms (SNPs) linked to SLE are components of non-
coding DNA regions of immune response-related genes[40, 41]. Some genes are 
specific to SLE whilst others have been linked with several other autoimmune diseases 
(i.e. PTPN22 with diabetes and Graves thyroiditis)[42]. Certain SNPs associated with 
SLE have been identified to contribute to aberrant dendritic cell function and IFN 
signalling (TREX1 and STAT4); whilst others are linked to dysfunction of immune-
complex processing and innate immunity such as impaired interleukin (IL) expression 
(C1QA, ITGAM); T cell function and signalling (STAT4 and PTPN22); cell cycle, 
apoptosis and cellular metabolism (CASP10); and transcriptional regulation (MECP2) 
in SLE[32]. Although the literature is growing, the loci identified so far can only account 
for about 15% of the heritability of SLE[43]. An altered copy number of certain genes, 
such as FCGR3B[44], TLR7[45], and C4[46] which influences gene dosage has also 
been linked to SLE disease expression.    
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Environmental factors are known to initiate SLE disease and activity. Epigenetic 
changes through DNA hypomethylation due to exposure to certain medications (i.e. 
tetracyclines) can induce the onset of SLE, which is sometimes defined as drug-
induced SLE[47]. Smoking and ultraviolent light increase the risk of SLE through 
unknown mechanisms[48]. Viral infection, such as with the Epstein-Barr virus (EBV), 
have been implicated in epidemiological studies in the initiation and exacerbation of 
SLE through the potentiation of aberrant innate immune pathways[49]. Female 
hormones contribute to the increased prevalence of SLE in women[50]. Pregnancy and 
exogenous oestrogen or progesterone administration increases the severity of SLE, 
however the mechanism of how hormones influence SLE is unknown. The X 
chromosome may be an independent SLE risk factor based on castrated X 
chromosome knockout murine models. Mouse models manipulated to express XX or 
XXY combinations, compared to XO or XY combinations, were found to have increased 
severity in SLE[51].       
DNA methylation and histone modification contribute to DNA accessibility and thus 
gene expression; contributing to the development of lupus in healthy persons. 
Hydralazine and procainamide inhibit DNA methylation and are linked with a lupus 
variant called drug-induced lupus. Hypomethylation of the regulatory region of genes 
involved in disease pathogenesis (ITGAL, CD40LG, CD70, and PPP2CA) have been 
reported in SLE[32]. Experimental treatment in lupus-prone mice with an inhibitor of 
histone deacetylase, Trichostatin A, has been shown to improve disease through the 
blockade of histone deacetylase-mediated recruitment and suppression of the IL-2 
promoter[52].      
Innate and adaptive immune responses are pathogenic in patients with SLE, where 
early signalling events are amplified or primed[53]. Pathways implicated include T cells, 
lipid rafts, IL17, adhesion molecule CD44, CXCR4 receptors, plasma cells, 
autoreactive B cells; normal and plasmacytoid dendritic cells (pDCs), IFN, and loss of 
inhibitory immune pathways for IL-2. The resultant impact is the development of 
damaging immune complexes composed of that antinuclear antibody bound to nuclear 
tissue deposit into tissues and organs. These complexes arise in large amounts in 
blood and tissues and are slow to clear due to numerical and functional depletion in Fc 
and complement receptors. In the renal glomeruli, sequential deposition of immune 
complexes into the subendothelial and mesangial areas first, followed by deposition in 
the basement membrane and subepithelial areas is seen[32]. Immune deposition has 
also been shown in the tissue beds of skin and the central nervous system. Immune 
complexes may bind to receptors expressed by tissue-specific cells and alter their 
function, however more prominently, the complexes activate the influx of immune cells 
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and the complement cascade, generating localised inflammation. The mix of migrant 
peripheral T cells, polymorphonuclear cells and B cells contribute towards the local 
auto-inflammation and feedback to the overall autoimmune process.          
Non-immune cells contribute to disease expression through facilitating antigenic 
presentation with an increase in secretion of pro-inflammatory cytokines. This has been 
observed in renal glomerular cells when exposed to IFN-γ, and keratinocytes following 
exposure to ultraviolet light for which the latter become apoptotic and release nuclear 
material[32]. The expression of additional organ-specific molecules is influential in 
determining the pattern of organs or tissue involvement in lupus. Expression of tumour 
necrosis factor (TNF) receptor 1 is linked with lupus skin disease, however is protective 
against lupus nephritis (LN) [54].    
2.2.1.4 SLE and the antinuclear autoantibody spectrum 
Antibodies against nuclear antigens are a pre-requisite diagnostic feature of SLE and 
form one of the immunological criteria of both the ACR-97 and SLICC-12 SLE 
classification criteria (Table 1). There are a wide spectrum of autoantibodies specific to 
lupus and some autoantibody specificities have well-recognised clinical associations, 
such as ribosomal P antibody and lupus cerebritis[32]. Antibodies against 
phospholipids and β2-glycoprotein 1 are sometimes present in patients with lupus 
however are indicative of the antiphospholipid syndrome (APLS) which features 
recurrent thrombosis and pregnancy morbidity. An in-depth discussion of ANAs is 
detailed in Chapter 2.3.6.  
 
Within the lupus autoantibody specificities only a few have site-specific effects linked 
with manifestations of lupus disease. Anti-T-cell antibodies are associated with the 
suppression of IL-2 production. Anti-blood-cell antibodies are linked with cytopaenia. 
Lupus nephritis is associated with anti-DNA antibodies, antibodies against the 
collagen-like region of C1q, anti-nucleosome antibodies and the presence of anti-
chromatin antibodies. Anti-Ro antibodies have a predilection for myocytes and the 
cardiac conduction system and are associated with congenital foetal heart block. Some 
anti-DNA antibodies cross-react with cerebral cell-specific antigens (i.e. N-methyl-d-
aspartate receptors), and increase the risk of lupus cerebritis and neurocognitive 
defects.       
2.2.1.5 SLE treatment pathways 
Patients with SLE are treated with a range of anti-inflammatory, antiplatelet, 
immunomodulatory and immunosuppressive therapeutics (Table 2). This includes non-
steroidal anti-inflammatory drugs (NSAIDs), antimalarial agents, glucocorticoids, 
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disease modifying anti-rheumatic drugs (DMARDs) and other immunosuppressive 
drugs[55].  
Table 2 Therapeutics in SLE(56, 57) 
NSAIDs 
Immunosuppressive agents 
Glucocorticoids, Cyclophosphomide, Methotrexate, Azathioprine 
Mycophenolate mofetil, Tacrolimus and calcineurin inhibitors 
Modulators of B cell function or numbers 
B cell depletion (Rituximab)  
B-lymphocyte stimulator inhibitor (Belimumab) 
Inhibition of Toll-like receptors (TLRs) 
Hydroxychloroquine and related drugs 
Avoidance of exogenous oestrogen and/or progesterone 
Table 2. Therapeutics in SLE. 
2.2.2 Primary Sjӧgren’s syndrome 
Primary Sjӧgren’s syndrome (pSS) is a systemic autoimmune disease characterised by 
lymphocytic infiltration of the secretory glands[56]. Sicca syndrome is the central 
diagnostic feature which presents as dryness of the eyes, oral cavity, pharyngolarynx 
and/or vagina. Extra-glandular manifestations may be concurrent in patients with pSS 
including cutaneous, musculoskeletal, pulmonary, renal, haematological and 
neurological involvement. Constitutional symptoms such as fatigue, glandular swelling 
and night sweats are common features. The syndrome may present secondary to 
another autoimmune disease such as SLE or rheumatoid arthritis (RA) in which case it 
is referred to as secondary Sjӧgren’s syndrome (sSS). The prevalence of sSS is 
highest in RA and estimated to be approximately 20%[57]. The incidence of pSS is 
approximately 4 per 1000 patients per year and overall prevalence of pSS in Europe is 
between an estimated 0.1-4.8%[58]. 
2.2.2.1 Primary Sjӧgren’s syndrome pathogenesis 
As in SLE, the pathogenesis of pSS is multifactorial and not fully understood. 
Autoreactive Th1 cells against variants of the major histocompatibility complex class 2 
molecule is thought to have a key role in the pathogenesis of pSS, with autoreactive T 
helper 17 (Th17) cells[59], Th1 cell cytokines (IL-1b, IL-6, TNF-α and IFN-γ)[60], IL-17 
(a Th17 cytokine)[61], and autoreactive B cells contributing to the maladaptive 
response. The innate immune system is considered to have an initiating role in the 
autoimmune process of pSS. One of the key mechanisms is increased TLR activity and 
the excessive expression of IFN type I and II by pDCs[62, 63]. It has been suggested 
that certain viruses (i.e. EBV) and immune complexes activate the maladaptive innate 
immune processes, although the evidence is indirect[64, 65]. B cell activating factor 
(BAFF) is stimulated in the presence of type I and type II IFN and this is thought to 
contribute to the B cell autoreactivity and consequential expression of 
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hyperglobulinaemia and immune complex formation in pSS[66]. In pSS patients, 55% 
have an increased IFN type I activity in CD14 monocytes compared to 4.5% in healthy 
controls[67]. Increased IFN-I activity in pSS has been correlated with higher EULAR 
Sjӧgren’s Syndrome Disease Activity Index (ESSDAI), increased levels of IgG and/or 
hypocomplementaemia, and raised levels of BAFF mRNA in monocytes[63, 67].  
2.2.2.2 Primary Sjӧgren’s syndrome diagnostic and classification criteria  
Diagnostic criteria have not been developed for pSS or sSS however there are 
classification criteria which have a principle role in supporting participant homogeneity 
in pSS research. Primary Sjӧgren’s syndrome can be classified in accordance with the 
2002 American-European Consensus Criteria for Sjӧgren’s syndrome [68] (Table 3). 
These criteria include the presence of dry ocular or oral symptoms (item I and II), 
supportive ocular signs based on either an abnormal Schirmer’s test or a positive vital 
dye staining of the eye surface (item III); a lip biopsy showing focal lymphocytic 
sialoadenitis (item IV); supportive oral signs of either unstimulated whole salivary flow 
or abnormal parotid sialography (item V); or the anti-SSA (Ro) or anti-SSB (La) or both 
autoantibodies (item V). For a pSS diagnosis, any four of the six criteria, including item 
IV (histopathology) or VI (autoantibodies) must be present, or any 3 or the objective 
criteria (item III, IV, V or VI) in the absence of exclusion criteria. For a sSS diagnosis, 
the presence of a well-defined major CTD and one symptom (either item I or II) plus 
two of the three objective criteria is indicative (Item III, IV and V). In 2016 ACR and 
EULAR jointly developed a new set of classification criteria for primary Sjӧgren’s 
syndrome[69]. The classification of SS is based on five objective items and is met in 
patients who have a score of ≥4 [70].          
Table 3 American-European Consensus Criteria for Sjögren’s Syndrome and the 
ACR Classification criteria for Sjӧgren’s syndrome[69-71] 
American-European Consensus Criteria for Sjogren’s Syndrome  
Item I: Ocular symptoms (≥1): Symptoms of dry eyes for ≥3 months, a foreign body 
sensation in the eyes, or use of artificial tears ≥3 times per day 
Item II: Oral symptoms (≥1): Symptoms of dry mouth for ≥3 months, recurrent or 
persistently swollen salivary glands, or need for liquids to swallow dry foods 
Item III: Ocular signs (≥1): abnormal Schirmer’s test, (without an aesthesia; ≤5 mm/5 
minutes) or positive vital dye staining of the eye surface 
Item IV: Histopathology: Lip biopsy showing focal lymphocytic sialadenitis (focus 
score ≥1 per 4 mm2) 
Item V: Oral signs (≥1): Unstimulated whole salivary flow (≤1.5 mL in 15 minutes) or 
abnormal parotid sialography, abnormal salivary scintigraphy 
Item VI: Autoantibodies (at least one): Anti-SSA (Ro) or Anti-SSB (La), or both 
Exclusion criteria 
Past head and neck radiation treatment, hepatitis C infection, acquired 
immunodeficiency syndrome (AIDS), pre-existing lymphoma, sarcoidosis, graft versus 
host disease, and/or current use of anticholinergic drugs 
2016 ACR/EULAR Classification criteria for primary Sjӧgren’s Syndrome 
1. Labial salivary gland biopsy exhibiting focal lymphocytic sialadenitis with a focus 
score ≥1 focus/4 mm2 (weight 3) 
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2. Positive serum anti-SSA/Ro (weight 3) 
3. Ocular Staining Score ≥5 (or van Bijsterveld score ≥4) in at least 1 eye (weight 1) 
4. Schimer’s test ≤5 mm/5 min in at least 1 eye (weight 1) 
5. Unstimulated whole saliva flow rate ≤0.1 mL/min (weight 1)  
Inclusion criteria: Any patient with ≥1 symptom of ocular or oral dryness, defined as 
a positive response to ≥1 of the following: (1) Daily, persistent, troublesome dry eyes 
for ≥3 months, (2) recurrent sensation of sand or gravel in the eyes, (3) use of tear 
substitutes ≥3 times a day, (4) daily feeling of dry mouth for ≥3 months, (5) frequent 
use of liquids to aid in swallowing dry food, or (6) the suspicion of SS from the EULAR 
SS Disease Activity Index. 
Table 3. Classification criteria for pSS. 
2.2.2.3 Primary Sjӧgren’s syndrome treatment pathways 
Table 4 lists some of the local and systemic treatment options in SS[72]. Most of the 
agents recommended for the treatment of sicca symptoms are supported by Grade A 
evidence (meta-analyses or at least one randomised controlled trial) whilst systemic 
therapies are supported by either Grade C or D level evidence (one well-designed 
descriptive study or case-control study; or expert option)[73]. 
Table 4 Therapeutic options in Sjögren’s syndrome(72) 
Site Therapeutic options 
Keratoconjunctivitis sicca Tear substitutes, secretagogues, cyclosporine A eye 
drops, topical corticoisteroids or punctal plugs 
Xerostomia Patient education, avoid xerostomia-inducing drugs, 
secretagogues, saliva substitutes or stimulants 
Parotid swelling Corticosteroids or antibiotic treatment if required 
Arthritis NSAIDs, corticosteroids, DMARDs  
Interstitial lung disease (ILD) Corticosteroids, cyclophosphamide 
Tubulointerstitial nephritis Potassium and bicarbonate replacement 
Glomerulonephritis Corticosteroids, cyclophosphamide, mycophenolate  
Neuropathy Corticosteroids, intravenous immunoglobuin 
Cryoglobulinaemic vasculitis Corticosteroids, plasmaphoresis 
Table 4. Management options in SS.  
2.2.3 Systemic sclerosis 
Systemic sclerosis (SSc) is a heterogenous immune-mediated rheumatic disease that 
is characterised by three hallmarks: small vessel vasculopathy, production of 
autoantibodies, and fibroblast dysfunction leading to increased deposition of 
extracellular matrix[74]. It is the fourth most common systemic autoimmune CTD after 
RA, SLE and pSS[75]. The estimated prevalence of SSc is 1 in 10,000[76, 77]. The 
clinical prognosis and features vary, however fibrotic skin thickening is the central 
feature which occurs with variable involvement of the internal organs[78]. Additional 
features are Raynaud’s phenomenon, digital ulcers, gastro-oesophageal reflux 
disease, interstitial lung disease, and pulmonary arterial hypertension. Sine 
scleroderma is a variant of SSc and is recognised as internal fibrosis in the absence of 
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skin involvement. Systemic sclerosis has a high mortality, especially in the diffuse SSc 
form and with multiple organ-based involvement[78, 79].     
2.2.3.1 Systemic sclerosis diagnostic and classification criteria  
There is no diagnostic criterion for SSc however classification criteria exist. The 2013 
ACR-EULAR criteria for the classification of systemic sclerosis require a total score of 
≥9 for a definite classification[80] (Table 5). Subsets of SSc can be discerned based on 
the extent of cutaneous sclerosis relative to the knee and elbow. Proximal cutaneous 
sclerosis is classified as diffuse cutaneous systemic sclerosis (diffuse SSc), whereas 
the restricted form known as limited systemic sclerosis (limited SSc) affects the limbs 
distal to the elbows or knees, and can be with or without facial and neck involvement. 
The importance of the major subsets of SSc is that there are typical expectant features 
(Table 6) for which specific disease monitoring and treatment is required.      
Table 5 2013 ACR-EULAR criteria for the classification of scleroderma(80) 
Proximal skin involvement: Skin thickening of the fingers of both hands, 
extending proximal to the metacarpophalangeal joints (9) 
Skin thickening of the fingers: Puffy fingers (2); Sclerodactyly of the fingers (4)  
Fingertip lesions: Digital tip ulcers (2); Fingertip pitting scars (3) 
Telangiectasia (2) 
Abnormal nailfold capillaries (2) 
Pulmonary arterial hypertension or interstitial lung disease: Pulmonary arterial 
hypertension (2); Interstitial lung disease (2)  
Raynaud’s phenomenon (3) 
Systemic sclerosis-related autoantibodies: Anti-centromere (3), Anti-
topoisomerase I (3), Anti-RNA polymerase III (3) 
Table 5. SSc classification criteria. Score in (brackets). 
Table 6 Typical features of the major subsets of scleroderma(80) 
Limited SSc 
Distal skin sclerosis 
Long history of Raynaud’s phenomenon 
Late-stage complications frequent 
Pulmonary arterial hypertension and severe gut disease frequent 
Diffuse SSc 
Proximal limb or trunk involvement, with skin sclerosis 
Short history of Raynaud phenomenon 
Increased risk of renal crisis and cardiac involvement 
High frequency of severe lung fibrosis 
Table 6. Major SSc subsets. 
2.2.3.2 Systemic sclerosis pathogenesis  
The pathogenesis of SSc is complex and multifactorial. A combination of causal 
factors, genetic susceptibility and epigenetic alterations probably underlies the initiation 
and continuation of the disease. Several immune-regulatory genes have been identified 
that might contribute to the susceptibility of SSc and its specific associations[76, 77]. 
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Case reports and series have linked certain organic chemicals and pesticides as 
environmental risk factors in the development of SSc, in particular vinyl chloride, 
chemotherapy drugs, such as taxanes, and radiotherapy exposure[81]. The evidence is 
conflicting for silicone breast implants, suggesting no association or that the 
association occurs however only as a rare event in susceptible individuals[82]. Many 
studies have found an association between the onset of SSc and a range of solid and 
non-solid organ malignancies, most commonly in association with the anti-RNA 
polymerase antibody, and particularly in patients with rapid-onset, severe disease[83].  
A growing body of literature is providing insight into the molecular and biological 
mechanisms of SSc. The current concept is that SSc is the manifestation of persistent 
and self-sustaining myofibroblast activation, resulting in skin and organ fibrosis of 
variable severity. A milieu of cells are involved including monocytes, T helper cells, 
local fibroblasts and myofibroblast precursors together with localised induction and 
overexpression of a range of cytokines and chemokines. Mechanical stress in the 
extracellular matrix, autocrine stimulation and epigenetic changes result in persistence 
of myofibroblasts through failure of apoptosis and ongoing extracellular matrix 
overproduction[84]. Current strategies to manage SSc include general 
immunosuppression with more recent therapies specifically targeting cytokines and 
growth factors implicated in disease pathogenesis. However, none of these 
approaches have been shown to be curative and all have consequential off-target 
effects.   
2.2.3.3 Systemic sclerosis treatment pathways 
Modern management of SSc relies on detailed baseline assessment and follow-up 
tailored to the early identification of specific and important complications of SSc[74]. 
Immune-modulating therapies is used in accordance with the site of affected tissue or 
organ. Haematopoietic stem cell transplantation (HSCT) has evidence as a treatment 
option for interstitial lung disease or severe organ involvement which has failed to 
improve with conventional immunosuppressive agents. The treatment-related mortality 
for HSCT is a limiting factor in its use. Other agents include drugs to improve perfusion 
in digital vasculopathy, anti-reflux treatment, pulmonary hypertension therapies, and 
prokinetic, cyclical antibiotics and dietary adjustment in gastrointestinal disease.  
2.2.4 The inflammatory myopathies 
Inflammatory myopathies (IM) are a heterogeneous group of autoimmune disorders 
characterised by muscle inflammation and variable extra-muscular involvement of the 
skin, lung and joints. Distinct subsets are recognised including dermatomyositis (DM), 
immune-mediated necrotising myopathy (IMNM), inclusion-body myositis (IBM), 
overlap myositis (including the anti-synthetase syndrome), and polymyositis (PM). The 
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discovery of a wide range of autoantibodies has advanced the understanding and 
identification of these rare systemic autoimmune conditions.  
2.2.4.1 Inflammatory myositis diagnosis and classification criteria 
There are no diagnostic criteria for IM. The 1975 Bohan and Peter criteria are the most 
widely used classification criteria but were recently superseded by the 2017 
EULAR/ACR classification criteria[85] for adult and juvenile IM[86, 87]. The Bohan and 
Peter criteria classified DM from PM as either ‘definite’, ‘probable’ or ‘possible’ and 
incorporated qualifying criteria from electromyography, biopsy and biochemistry 
investigations while importantly including certain exclusion criteria to eliminate IM 
mimickers (Table 7) [86, 87]. These criteria were revisited following the description of 
new clinical subsets of IM and deeper understanding of IM pathophysiology. The 
EULAR/ACR criteria for adult and juvenile IM published in 2017 (Table 8) aim to 
categorise IMs into the major subgroups using highly discriminatory clinical and 
laboratory criteria[88]. A calculated score based on the weighting of 16 variables 
presents the probability of an individual to have a particular subtype of IM. An online 
calculator for the 2017 EULAR/ACR criteria for adult and juvenile IM is available online 
[89]. 
There are differences in publications as to which auto-antibodies are to be included in 
myositis-specific autoantibody (MSA) and myositis-associated autoantibody (MAA) 
definitions, however MSAs are considered to be relatively specific autoantibodies for 
myositis, while MAAs may be associated with other or overlap forms of  CTD[90]. Once 
the phenotype of myositis is confirmed, and organ involvement defined, the 
management is tailored towards the disease features and severity. This includes the 
cancer-associated subtype of IM which requires concurrent investigation for 
malignancy[91]. 
Table 7 1979 Bohan and Peter criteria for DM and PM[86, 87] 
1. Symmetrical weakness, usually progressive, of the limb-girdle with or without 
dysphagia and respiratory muscle weakness 
2. Muscle biopsy evidence of myositis: necrosis of type I and type II muscle fibres; 
phagocytosis, degeneration, and regeneration of myofibers with variation in 
myofiber size; endomysial, perimysial, perivascular, or interstitial mononuclear cells  
3. Elevation of serum levels of muscle-associated enzymes  
4. Electromyography triad of myopathy 
a. Short, small, low-amplitude polyphasic motor unit potentials 
b. Fibrillation potentials, even at rest 
c. Bizarre, high-frequency repetitive discharges 
5. Characteristic rashes of DM 
 Definite PM: all first 4 elements, probable PM: 3 of first 4, possible PM: 2 of first 4.  
 Definite DM: characteristic rash plus 3 others, probable DM: rash plus 2 others 
 Possible DM: rash plus 1 other 
Table 7. Classification criteria for IM. 
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Table 8 Components of the 2017 EULAR/ACR criteria for adult and juvenile IM[88] 
When no better explanation for the symptoms and signs exists these classification 






Age of onset of first symptom ≥ 18 and < 40 years 1.3 1.5 
Age of onset of first symptom related to the disease ≥ 40 years 2.1 2.2 
Objective symmetric weakness, usually progressive, of the 
proximal upper extremities 
0.7 0.7 
Objective symmetric weakness, usually progressive, of the 
proximal lower extremities 
0.8 0.5 
Neck flexors are relatively weaker than neck extensors 1.9 1.6 
In the legs, proximal muscles are relatively weaker than distal 
muscles 
0.9 1.2 
Heliotrope rash 3.1 3.2 
Gottron’s papules 2.1 2.7 
Gottron’s sign 3.3 3.7 
Dysphagia or oesophageal dysmotility 0.7 0.6 
Anti-histidyl-tRNA synthetase autoantibody present 3.9 3.8 
Elevated serum levels of muscle-associated enzymes 1.3 1.4 
Endomysial infiltration of mononuclear cells surrounding, but 
not invading, myofibres 
 1.7 
Perimysial and/or perivascular infiltration of mononuclear cells  1.2 
Perifascicular atrophy 1.9 
Rimmed vacuoles 3.1 
Table 8. EULAR/ACR Classification criteria of IM.  
The heterogeneity of the inflammatory myopathies lends itself to a long and complex 
discussion of IM pathogenesis. As IM pathogenesis is not the focus of this thesis, this 
chapter will provide a concise description of pathogenic processes for each of the 
major subtypes of IM. Similar to other conditions on the CTD spectrum, a combination 
of genetic risk and environmental exposures is thought to trigger and potentiate the 
disease process through immunological and non-immunological processes[92]. With 
the exception of IBM, female gender appears to be a risk factor in reflection of the 
increase rates in women compared to men[93]. 
The pathognomonic skin features of DM include a violaceous periorbital rash 
(heliotrope rash) and erythematous lesions on the extensor surfaces of the joints 
(Gottron’s papules)[94]. There is a form of DM called sine DM dermatitis that manifests 
with cutaneous involvement in the absence of muscle involvement. In classical DM, 
muscle enzymes are usually elevated and electromyography (EMG) demonstrates a 
myopathic pattern. A highly specific feature of DM is perifasicular atrophy on muscle 
biopsy (specificity >90%, sensitivity 25 - 50%). Perifasicular human myxovirus 
resistance protein 1 and retinoic acid-inducible gene 1 (sensitivity 71%, specificity 50%) 
can also be detected in addition to histological changes of cellular infiltrates consisting 
of pDCs, B cells, CD4 T cells, and macrophages in >80% of samples. The cellular 
infiltrate tends to aggregate around medium-sized blood vessels and the perimysium, 
which is a hallmark finding in DM. Approximately 70% of patients with DM will have a 
detectable dermatomyositis-specific autoantibody[92]. In the case of positivity for anti-
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NXP2 or anti-transcription intermediary factor antibodies there is an associated 
increased risk of malignancy that manifests in approximately 20% of individuals within 
three years of diagnosis. Cancer-associated DM is proposed to have an off-target 
immune mechanism  related to molecular mimicry[95]. In terms of risk factors in DM, 
certain class-2 HLA alleles and exposure to ultraviolet light have been implicated[94].  
IMNM is a distinct subtype of IM characterised by proximal muscle weakness, extreme 
muscle enzyme concentrations, myopathic EMG findings, and muscle biopsies 
showing necrosis or regeneration with minimal lymphocyctic infiltrate in the absence of 
perifasicular atrophy[94]. Typical histological changes include type 1 major 
histocompatibility complex upregulation, macrophage infiltration, and membrane attack 
complex deposition on non-necrotic muscle fibres. Around 60% of IMNM patients have 
autoantibodies recognising either signal recognition particle (SRP) or 3-hydroxy-3-
methylglutaryl coenzyme A reductase (HMGR) in which case 20% of these cases are 
positive for lymphocytic infiltrates on muscle biopsy. Autoantibody-positive IMNM is 
clinically indistinguishable from autoantibody-negative IMNM with the exception that 
anti-HMGCR IMNM is associated with statin exposure, and anti-SRP IMNM tends to 
have more severe muscle weakness, higher rates of ILD (12-22% versus <5%) and 
tissue specimens showing a higher density of necrotic fibres. A cancer association 
exists for both anti-HMGCR myositis and antibody-negative myositis, unlike anti-SRP 
myositis. Regarding immunogenetic risk factors in IMNM, class-2 HLA-allele 
DRB1*08:03 is associated with anti-SRP myopathy, and DRB1*11:01 with anti-
HMGCR myopathy. Given these observations, increased HMGCR production has been 
proposed to contribute to breaking tolerance for the development of HMGCR 
myopathy. Statins, which inhibit the enzymatic activity of HMGCR and increase the 
production of HMGCR, are proposed to induce myopathy through this mechanism or 
alternatively through the generation of a neo-epitope that triggers an immune response.  
Similar to other types of inflammatory myopathies, the presentation of IBM is a 
combination of elevated muscle enzyme concentrations and myopathic EMG 
features[94]. Severe involvement of the anterior compartment of the thigh is a 
distinctive MRI characteristic. IBM is a unique disease however in that the proposed 
mechanistic process may not be autoimmune but rather a degenerative process. IBM 
differs to other myopathies in that it has a comparatively older age at onset (>50 
years), slow progression over years (not weeks or months), an asymmetrical pattern of 
muscle involvement, and selective knee extensor and distal weakness especially of the 
deep finger flexors, wrist flexors, ankle dorsiflexors (compared to proximal 
involvement). IBM is not associated with any MSA although antibodies against 
cytosolic 5’-nucleotidase 1A (anti-NT5C1a) are present in 30 - 60% or patients in IBM 
compared with 5-10% of patients with PM, 15-20% of patients with DM, 10% of patients 
with SLE and 12% of patients with SS[96, 97]. The collective disposition however is 
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that immunosuppression does not benefit patients with IBM, compared to the other 
IMs[93]. The histological characteristics pathognomonic of IBM is co-existing 
inflammation, mitochondrial dysfunction and abnormal protein aggregation. The 
inflammatory infiltrate is dominated by CD8 T cells that surround and invade non-
necrotic muscle fibres. There is an increased presence of ragged-red and cytochrome 
oxidase-negative muscle fibres, supporting that theory that mitochondrial damage has 
an important role in IBM. Other distinctive histological hallmarks include rimmed 
vacuoles, which remain unknown in aetiology, and cytoplasmic inclusions which are 
representative of amyloid protein and give rise to the name inclusion-body myositis.  
Although not specific to IBM, anti-NT5C1a autoantibodies have been associated with 
increased severity and mortality in patients[98, 99]. It lends support to the idea of an 
autoimmune origin for IBM, together with the T cell infiltrate seen on histopathology. 
However the presence of cytoplasmic inclusions and the observation that 
immunosuppression is ineffective suggests an underlying degenerative process for 
which to decipher future investigations are necessary. 
Overlap myositis is a subtype of inflammatory myopathy that represents the co-
existence of myositis with another CTDs[93, 94]. Myositis may coincide with features of 
another autoimmune disease such as SLE, pSS or SSc and their associated 
autoantibodies. Anti-synthetase syndrome is the most representative form of overlap 
myositis and typically manifests with autoantibodies directed against aminoacyl tRNA 
synthetase enzymes. Patients with anti-synthetase syndrome usually present with one 
or more of the following features: inflammatory myopathy, ILD, arthritis, Raynaud 
syndrome, fever, or hyperkeratotic radial fingers lesions known as mechanics hands. 
Muscle enzyme levels and EMG findings are similar to DM. The muscle biopsies of 
these patients however reveal both perivascular atrophy and necrosis with nuclear 
actin aggregation, an electron microscopy feature, that is not seen in other IMs. 
However little is known about what triggers and maintains autoimmunity in anti-
synthetase syndrome, and further research is warranted.  
Polymyositis has the presence of muscle weakness, raised muscle enzymes, 
myopathic EMG findings, and CD8 T cell inflammatory infiltrates on muscle biopsy with 
none of the hallmark characteristics of the other inflammatory myopathies[94]. PM 
often remains a diagnosis of exclusion and surveillance for clinical features to suggest 
an alternative subtype of inflammatory myositis is often recommended. 
2.2.4.2 Inflammatory myositis treatment pathways 
The challenge of IM is identifying a suitable treatment. Supportive research for 
treatment selection is limited in light of the low prevalence and wide phenotypic 
heterogeneity of IM[94]. As previously mentioned, the literature does not support 
immunosuppressive treatment for IBM and a recent Cochrane review highlighted this in 
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addition to the scarcity of high-quality randomised controlled trials for the treatment of 
non-inclusion body myopathies. Leading treatment pathways currently follow expert 
consensus or case-series and historical clinical practice. Individualised physical 
exercise programs under the supervision of a physical therapist is supported by two 
randomised controlled trials as a way to improve strength and reduce disability. A 
summary of treatment modalities is provided in Table 9. 
Table 9 Treatment options for inflammatory myopathies other than IBM[92] 
Immunosuppressant or immunomodulatory agents 
Corticosteroids, Azathioprine, Methotrexate, Ciclosporin, Tacrolimus,    
Mycophenolate mofetil, Cyclophosphomide, Intravenous immunoglobulin 
Biological agents 
Rituximab, Abatacept, Tocilizumab 
Table 9. Treatment options in IMs other than IBM.  
2.2.5 The non-traditional CTDs and CTD-variants 
The categorisation of CTDs into SLE, SS, SSc and IM has the purpose of defining 
distinct disease entities and standardising CTD practice pathways. The classification 
systems of SLE, SS, SSc and IM differ in intent however, in that their purpose is to 
facilitate homogeneous and reproducible clinical research such that results are 
transferrable to a specific population. However, on occasion, the clinical features of a 
patient with systemic autoimmune rheumatic disease may be suggestive of a CTD, and 
warrant treatment along the pathway of a CTD, but defy categorisation or classification 
into any one defined entity. In this instance, the variation in presentation and evolution 
of the CTDs is apparent and highlighted are the short-comings of the current CTD 
classification and nomenclature systems. This chapter will discuss the non-traditional 
CTDs and CTD-variants including MCTD, OCTD and UCTD. 
2.2.5.1 Mixed connective tissue disease diagnosis and classification  
Mixed connective tissue disease (MCTD) is a term used to describe a subset of overlap 
CTD that is characterised by the presence of high-titre autoantibodies against 
ribonucleoproteins (anti-RNPs)[28]. The includes autoantibodies directed against the 
whole protein complex (U1-snRNP), the U1-RNA subcomponent, core Sm proteins, or 
U1-specific proteins (U1-70K, U1-A and U1-C). There is still no consensus regarding 
the disease definitions, the classification criteria, or the relationship of MCTD with other 
CTDs. Some authors argue that MCTD is a distinct disease entity, while others 
consider it to be an overlap syndrome or an early underdeveloped phase of a more 
distinct CTD, and few even still disregard the entire concept of MCTD[100].   
There are no uniform guidelines for the definition of MCTD. The requirement for RNP 
autoantibodies in itself is contentious as the literature provides conflicting data on the 
relevance of the autoantibody. Anti-RNP antibody titres have been correlated with 
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activity in MCTD[101], including the regression of activity following treatment 
(p<0.046)[102]. The RNP autoantibody however is not exclusive to MCTD and may be 
detected in patients meeting criteria for SLE (20 - 40%), SSc (2 - 14%) and IM (6 - 9%). 
The original report of the concept of MCTD also lends itself to controversy. A review of 
the case series published in 1972 revealed inconsistencies in data reporting[101]. The 
anti-RNP antibody was absent in 3 of the 25 cases; excluded organ systems were 
evident and steroid requirements were high (and not low, as per definitions) in some 
cases; and prognosis could be seen to mirror SLE.  
The clinical features of MCTD include pulmonary hypertension, interstitial lung disease, 
oesophageal dysmotility, arthritis, “puffy hands” (diffuse hand oedema), leucopoenia, 
myositis, serositis, glomerulonephritis and Raynaud phenomenon[100]. Some authors 
propose the minimal diagnostic features should include anti-RNP autoantibody in a 
patient presenting with Raynaud phenomenon and puffy hands in addition to at least 
two of the aforementioned organ or tissue-based inflammatory features[100]. 
Diagnosing MCTD in clinical practice is therefore often based on pattern recognition 
and a clinical decision that is rich with potential for differences of opinion and practice 
across rheumatology communities.  
Four sets of classification criteria have been developed for MCTD which further 
complicate description of the disease entity. Shown in Table 10, the criteria by Sharp et 
al[103], Kasukawa et al[104], Alarcon-Segovia and Villareal[103], and Kahn and 
Appelboom[103] are distinctly different and do not capture the same patients according 
to Gunnarsson et al.[100]. Previous literature has reported the highest sensitivity and 
specificity in the Alarcon-Segovia and Villareal criteria[105] and the lowest in the Sharp 
et al criteria[103]. A longitudinal study of 161 MCTD patients over a mean period of 7.9 
years shed interesting light on the criteria[105]. The highest sensitivity in criteria was 
rather found to be apparent for Kasukawa et al. (75%), followed by Alarcon-Segovia and 
Villareal (73%) and then Sharp (42%)[106]. On longitudinal analysis rates were found to 
decrease when comparing the meeting of at least one of the three classification criteria 
from the time of diagnosis to the time of study exit. In detail, the rates for Kasukawa et al 
were 75% vs 53%, Alarcon-Segovia and Villareal 73% vs 44%, and Sharp 42% vs 32%. 
Of those that evolved, the rate included 17.3% progression into SSc, 9.1% into SLE, 
2.5% into RA and 11.5% into reclassified UCTD. The rate of evolution was seen highest 
in patients with disease durations >5 years than 0 - 5 years. This suggests that MCTD 
may misclassify an early, in development CTD. Although this conclusion markedly 
contrasts another longitudinal study of 280 MCTD patients for which new symptoms 
were observed however the classification remained unchanged[107]. The conflicting 




Table 10 Overview of the items included in the four published MCTD criteria sets[103, 105] 
Items Sharp Kasukawa et al. Alarcon-Segovia and Villareal Kahn and Appelboom 
Immunological  anti-U1RNP anti-RNP anti-RNP anti-RNP 
Raynaud 
phenomenon 
-one of four major criteria -one of two obligatory criteria -one of five clinical criteria -obligatory criteria 
Swollen/’puffy’ 
hands 
-one of four major criteria -one of two obligatory criteria -one of five clinical criteria -one of three clinical criteria 
Joint  Arthritis 
-one of 11 minor criteria 
Polyarthritis 
-one of five SLE-like findings 
Synovitis 
-one of five clinical criteria 
Synovitis 
-one of three clinical criteria 
Muscle  Myositis (mild) 
-one of 11 minor criteria 
≥1 of muscle weakness, 
elevated CK, or myogenic EMG 
-disease category (2/3 needed) 
Myositis (laboratory or biopsy 
proven) 
-one of five clinical criteria 
Myositis 




-can substitute swollen hands as 
one of four major criteria 
Sclerodactyly 
-one of three SSc-like findings 
Acrosclerosis (+/- scleroderma) 
-one of five clinical criteria 
Not included 
Lung  DLCO <70%, PAH or lung biopsy 
with proliferative vascular lesions 
-one of four major criteria 
Pulmonary fibrosis, vital capacity 
<80% or DLCO <70% 
-one of three SSc-like findings 




-can substitute Raynaud as one of 
the four major criteria 
Hypomotility or dilatation 
-one of three SSc-like findings 
Not included Not included 
Serositis Pleuritis or pericarditis 
-two of 11 minor criteria 
Pericarditis or pleuritis 
-one of five SLE-like findings 
Not included Not included 
Haematology Leukopaenia, anaemia, or 
thrombocytopaenia 
-three of 11 minor criteria 
Leukopaenia or 
thrombocytopaenia 
-one of five SLE-like findings 
Not included Not included 
Other Alopecia, trigeminus, neuropathy, 
malar rash, or history of swollen 
hands -four of 11 minor criteria 
Lymphadenopathy, or facial 
erythema 
-two of five SLE-like criteria 
Not included Not included 
Table 10. Classification criteria for MCTD.  
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2.2.5.2 Mixed connective tissue disease pathogenesis 
The proposed mechanisms of MCTD centres on a pathogenic role for anti-RNP 
antibodies. The autoantibody can bind to endothelial cells and cause endothelial cell 
activation and damage leading to vascular dysfunction[108]. The antibodies can also 
aggregate to form immune complexes and activate complement similar to other 
antibody-related diseases. B cell and plasma cell activity has been correlated with 
disease activity in MCTD[102]. A potential role for CD4+ IL-10+ regulatory T-cells 
and epitope spreading through B and T cell interactions and apoptosis-induced 
modifications has also been proposed[109]. 
The strongest evidence in support of MCTD as a distinct disease entity is the 
identification of unique HLA profiles in patients with MCTD that are distinctly 
different from the HLA profile of ethnically-matched healthy controls and the profile 
of SLE, SSc and IM[100]. There are, however, no functional data to explain how the 
HLA*B08 and DRB1*04:01 alleles may contribute to the formation of anti-RNP 
antibodies or MCTD pathogenesis. The generic mechanism of CTD development 
where a genetically “at risk” individual is exposed to a triggering environmental 
stimulus leading to the initiation of  CTD is considered to apply to MCTD, however 
data to identify an environmental risk factor is yet to published.  
2.2.5.3 Mixed connect tissue disease treatment pathways 
No randomised controlled trials of therapies for MCTD have been performed. 
Therapeutic selection is directed by the clinical manifestations and evidence base 
and experience from the treatment of other CTDs. The use of biological disease 
modifying anti-rheumatic in MCTD is based on case reports of the successful use of 
Rituximab. The initial case reports on TNF-alpha inhibitors indicated severe adverse 
effects but anecdotal expert recommendations suggest it is an option in treatment-
resistant arthritis[100].  
2.2.6 Overlap CTD (OCTD)  
The OCTDs have been identified as entities that satisfy the classification criteria of 
at least two CTDs and can occur either concurrently or sequentially in  the same 
patient[110]. There is no standardised definition or classification criteria has been 
accepted for OCTD. Some authors argue that the presence of at least one CTD if 
coincident with another autoimmune rheumatic disease is sufficient for the 
diagnosis. SLE, SSc, IM and SS are generally accepted in definitions for OCTD. The 
confusion for SS relates to the redundancy in nomenclature given that sSS is 
established as a co-existent disease in CTD. The same applies for MCTD and the 
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anti-synthetase syndrome which by nature are syndromic partnerships of CTD 
features. Certain autoantibody profiles lend towards OCTD (Table 11). Rhupus, a 
clinical condition in which in the same patient clinical signs and symptoms of both 
SLE and RA occur, is sometimes labelled as an overlap CTD. Whether RA is a true 
CTD and eligible under the umbrella of overlap CTD is a matter of debate. 
Table 11 Proposed classification of OCTDs(110) 
Associated with specific autoantibody profile 
MCTD (anti-RNP) 
Anti-synthetase syndrome (anti-tRNA synthetase) 
PM and SSc (anti-PM/Scl) 
SLE and sSS (anti-La/SSB) 
Not associated with specific autoantibody profile 
Rhupus syndrome; SSc /SS; SSc/RA; SLE/SSc; RA/SS; IM/SS 
Table 11. Proposed classification criteria of OCTDs.  
The identification of OCTD is useful to clarify the disease prognosis and facilitate 
management. By the influence of genetic and environmental factors, it is well known 
that autoimmune diseases tend to associated with each other. The therapeutic 
options in the overlap syndromes are as for the individual diseases and usually lead 
by specific organ features.   
2.2.7 Undifferentiated connective tissue disease 
Undifferentiated connective tissue disease (UCTD) is a term used to refer to an 
unclassifiable CTD which shares the clinical and serological manifestations of CTD 
but which does not fulfil any existing classification criteria[111]. It is a unique clinical 
entity and a potential forerunner of well-established CTD. Approximately 50% of 
patients presenting with CTD will have an unclassifiable profile at presentation[112]. 
The expectation is that a proportion of these patients will remain unclassifiable, 
others will regress into remission, and a further still will evolve into a definable CTD. 
The concept of UCTD replaces assumptive terminology  such as “incomplete”, 
‘atypical” or “evolving”  which fails to acknowledge transient disease cases and may 
lead the clinician towards misclassification and overtreatment[113]. It is well 
recognised that early diagnosis, prognostic profiling, and the timely initiation of 
therapeutic intervention are critical steps in the management of CTDs. The idea of 
UCTD as an entity is a means to facilitate these steps while avoiding misplaced 
management and enabling a period of observation.  
There are no standardised classification criteria or definitions for UCTD. Proposed 
criteria with short duration case definitions (i.e. less than 1 year) present the risk of 
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including transient diseases or diseases that are evolving into definite conditions, 
while longer case definitions fail to capture the UCTD population. There is no 
agreement on the accepted minimum symptom duration for case entry into UCTD 
and still no consensus on how best to identify patients with UCTD after disease 
onset. Mosca et al in 1999 proposed a preliminary set of classification criteria for the 
identification of UCTD. This included (1) signs and symptoms suggestive of a CTD 
but not sufficient to meet the criteria of a defined CTD; (2) positive ANA; and (3) a 
disease duration of at least 3 years[114]. It was suggested that the term ‘early 
UCTD’ could be adopted to refer to presentations with a disease duration of <3 
years. The criticism of the criteria is that while they allowed the exclusion of 
transitory conditions and early forms of developing CTD, the criteria were restrictive 
in that they excluded early UCTD at its onset and incomplete or overlap forms of 
CTD[115]. The Mosca group clarified that the criteria should be applied to define 
stable UCTD and offered to improve specificity with the introduction of exclusion 
criteria listing features specific for defined CTD[116] (Table 12). However the Mosca 
classification criteria have not been subject to validation and remain without wide 
acceptance within the rheumatology community.   
Table 12 Proposed  exclusion  criteria  for  UCTD(114) 
Clinical criteria 
Malar rash 













Anti-Jo1 or Anti-Mi2 
Table 12. Proposed exclusion criteria for UCTD.  
In terms of disease characteristics, stable UCTD is generally considered to be a 
benign disease which consequently requires only mild therapeutic intervention. It 
has a favourable prognosis and there is usually an absence of internal organ 
involvement. Life-threatening conditions and severe organ manifestations (such as 
renal or neurological disease) have been reported however these are not 
considered common within the disease spectrum[117, 118]. The manifestations of 
UCTD are described with wide variation in the literature (as would be expected) 
however most descriptions list Raynaud phenomenon, arthralgia/arthritis, skin 
rashes, photosensitivity, fatigue, sicca and mild cytopaenia as common features of 
the disease[118, 119]. Disease-specific ANA autoantibodies are less common and if 
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present are more likely to signify a developing definite CTD. Agreement exists on 
the fact that the majority of UCTD patients (80-99%) are female, with a mean age at 
disease onset ranging from 32 to 44 years[112]. The non-progression rate among 
UCTD cohorts appears to be approximately 30%, even in observational studies with 
ten year follow-up periods[114, 120-122]. The late evolution of UCTD into definite 
disease has been described however this is rare within the literature[112]. In those 
that progress, the highest rate of evolution into a definable disease is seen in the 
first and second year after the onset of symptoms. In UCTD cohorts with five year 
follow-up periods, approximately 34% of patients develop a well-defined rheumatic 
disease and 12.3% regress into complete remission[118]. In one study the 
diagnoses of the progressed cases were RA in 13.3%, pSS in 6.8%, SLE in 4.2%, 
SSc in 2.8%, MCTD in 4%, systemic vasculitis in 3.3% and IM in 0.5%; however, a 
range of autoimmune rheumatic conditions that are both within and not within the 
CTD spectrum have been reported by groups. This finding of diagnostic migration to 
another class of autoimmune rheumatic disease from the CTD spectrum has been 
reported in other cohorts and highlights the limitation of diagnostic imprecision in the 
UCTD concept[123].   
Several predictive factors for the evolution of UCTD into definite CTD have been 
identified. This offers insight into the features that may secure a definitive diagnosis 
and guides management and prognostication. Reports have been contrasting 
among the different cohorts however, and some studies have found negative results 
on analyses for prognostic factors however this could be a reflection of narrow 
cohort selection and short follow-up duration[112, 124]. The strongest predictors of 
evolution into a definitive CTD are high and multiple ANA autoantibody specificities 
and their accrual over time, as well as the presentation of symptoms and signs or 
laboratory abnormalities that are unique to a definitive CTD (i.e. Gottron’s papules, 
anti-Scl70 antibodies, puffy fingers). Evolution into SLE has been more specifically 
predicted by anti-dsDNA, Farr assay dsDNA antibody detection, Coomb’s test 
positivity, a positive test for syphilis, leucopaenia, African-American ethnicity, 
alopecia, discoid lupus, serositis, homogenous ANA, and antibody specificity for 
anti-Sm[125-131] (Table 13). The latter four factors were shown in a multivariate 
analysis to be independent predictive factors for SLE progression[125]. In terms of 
SSc, Danieli et al in 1998 in univariate analysis reported significant predictive factors 
in SSc to include sicca, Raynaud phenomenon, sclerodactyly, oesophageal 
dysfunction and ANA nucleolar pattern[126]. In the same study the prediction of SS 
was significant for Raynaud phenomenon, xerostomia, and anti-Ro/SSA. New 
pathological nailfold capillaroscopy pattern compared to baseline was also shown to 
be predictive of progression to defined CTD (p=0.01) and the retention of CTD 
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compared to remission (p=0.03)[132]. One group reported that “haemosiderin 
deposition/microhaemorrhages” (OR=8.32) and “elongated capillaries” (OR = 12.16) 
were independent variables especially predictive of progression to SLE (p<0.05). 
Table 13 Predictors of evolution of UCTD to define CTD 
Disease Predictive factor 
SLE High avidity anti-dsDNA detected on Farr assay[130] 
SLE Age, African-American ethnicity, alopecia, serositis, discoid lupus, 
Coomb’s test, anti-dsDNA, anti-Sm, ANA (homo)[125] 
SLE Leukopaenia, anti-dsDNA[128] 
SLE Anticardiolipin antibodies and multiple antibody specificities[129]  
SLE Age, fever, serositis, photosensitivity, ANA (homo) & anti-dsDNA[118] 
SLE Accumulation of autoantibodies[131] 
SLE Malar rash, oral ulcerations, anti-dsDNA (Farr assay), low C4[127] 
SLE Fever and anti-dsDNA antibodies[126] 
SSc Sicca, Raynaud phenomenon, sclerodactyly, oesophageal dysfunction, 
ANA nucleolar pattern[126] 
SS Raynaud phenomenon, xerostomia, anti-Ro/SSA[126] 
Table 13. Predictors of evolution of UCTD to CTD. Homo, homogenous.  
Triggering factors for UCTD and the evolution of UCTD into definite CTDs have 
limited evidence in the literature. Epidemiological reports indicate a significant 
association between Vitamin D deficiency and UCTD, as well as lower levels of 
Vitamin D in those who progress to well-defined CTD[133, 134]. In a study on the 
immune effects of Vitamin D insufficiency in patients with UCTD, supplementation 
with Vitamin D was reported to have the effect of reversing IL-17 expression and 
dampening T regulatory cell inhibition[135]. A dose-response study on the effects of 
Vitamin D supplementation on IL-17 and Th17 imbalance in UCTD patients with 
severe Vitamin D deficiency (<30 ng/ml) reported a dose threshold of 1.0 
micrograms/day over five weeks as the optimal therapeutic regime[136]. This data 
requires validation with a larger cohort however before their clinical incorporation. 
Implanted medical devices including silicone-containing implants and the non-
silicone-containing devices of artificial joints and orthopaedic metallic fixation 
devices were significantly associated with UCTD (OR 2.81, OR 5.01 and OR 1.95 
respectively) in a large case-control cohort of women[137]. In a small case-control 
study on obstetric patients with UCTD, pregnancy was associated with an increased 
risk of flare in UCTD and progression to a well-defined CTD[138]. 
The clinical course of UCTD is usually stable and with a favourable long-term 
prognosis. However, a recent study by Iudici M et al. showed that UCTD patients 
experienced an impaired quality of life in both functional and mental domains, 
similarly to SSc patients[10]. In this study, glucocorticoid exposure was significantly 
associated with improvements in physical and mental impairment (p < 0.001 and p = 
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0.043 respectively), although response to DMARDs was only observed for the 
mental domain (p = 0.037). In terms of obstetric morbidity, adverse pregnancy 
outcomes are reported within UCTD cohorts at an approximate rate of 20 - 40%, 
similar to conventional CTDs[138, 139]. Increased rates of low birthweight, 
spontaneous miscarriage, neonatal heart conduction disturbance, neonatal lupus, 
pre-eclampsia and medical intervention are reported across several observational 
and case-control cohort studies[139]. This data enriches the disease descriptions of 
UCTD and highlights the importance of quality of life and obstetric impact 
considerations.  
The literature suggests that careful management of UCTD patients is reasonable, 
but not always simple. Consideration of the severity of symptoms, stage of disease, 
the potential for organ damage, intervening factors for aggravation, and potential 
responses or side effects to therapeutic intervention must be weighed[113]. 
Management paradigms draw from the evidence base of the CTD spectrum. It is 
generally accepted that hydroxychloroquine is the mainstay of treatment in UCTD, 
however that a proportion of patients may require stronger immunosuppression and 
a further still no treatment at all[119]. There is low-level evidence to support the 
detection and supplementation of Vitamin D as a preventative strategy in CTD 
evolution[133].       
2.3 The pathogenesis of CTD: pre-clinical to definite CTD 
2.3.1 Introduction 
The developmental model of CTD is underpinned by a progressive process of 
autoimmune dysfunction that begins with an initiating event in a genetically pre-
disposed individual, to an asymptomatic pre-clinical phase, and then to early and 
established CTD[140] (Figure 3). The process is generally considered to be long, 
over several years[141]. Numerous genetic and environmental risk factors for CTD 
have been identified, and many of these are proposed to act as initiators or 
propagators of immune dysfunction before the clinical appearance of tissue injury. 
The preclinical phase of CTD is characterised by abnormalities in disease-related 
biomarkers including autoantibodies, cytokines and immune cell numbers and 
function. It represents a window of opportunity in which biomarkers to predict the 
risk of development of autoimmune disease and the introduction of preventative 
strategies may bear influence on outcomes. This chapter discusses the theoretical 
model of development of the CTDs  and includes discussion of genetic and 




Figure 3 The proposed development of autoimmunity in CTD(141) 
 
Figure 3. The proposed development of autoimmunity in CTD.  
2.3.2 Genetics in the development of CTD 
Established and emerging data demonstrate that the autoimmune process in CTD is 
a continuum that starts with genetic risk and progresses through a series of 
environmental interactions to phases of preclinical and clinical CTD (Figure 3)[140, 
141]. There is a strong genetic component in the pathogenesis of the CTDs; 
however, genetic risk alone is not enough to manifest the systemic rheumatic 
autoimmune diseases. Established and emerging data demonstrate that the 
autoimmune process in CTD is a continuum that starts with genetic risk and 
progresses through a series of environmental interactions to phases of preclinical 
and clinical CTD[140, 141]. There is a strong genetic component in the 
pathogenesis of the CTDs; however, genetic risk alone is not enough to manifest the 
systemic rheumatic autoimmune diseases.  
2.3.2.1 Twin concordance 
Family and twin studies on genetic risk where available have shown moderate to low 
concordance rates throughout the spectrum of CTDs. The heritability of SLE has 
been estimated at 66% with rates of concordance between 24% to 56% in 
monozygotic twins and 2% to 4% in dizygotic twins[142, 143]. The overall 
concordance in SSc in monozygotic and dizygotic twins has been reported at 4.7% 
Established CTD
Mature stage of disease and immune dysfunction
Early CTD
The individual shows non-specific or early signs of CTD as the immune dysfunction propagates
Pathogenic pre-clinical autoimmunity
A stage of maturation and amplification of the autoimmune process close to the onset of CTD
Benign pre-clinical autoimmunity
Environmental influences and positive feedback propagate the dysfunction in asymptomatic individuals
Genetic predisposition
Environment-gene interactions lead to autoimmune initiation in an asymptomatic individual
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and the familial risk in first degree relatives is estimated to be 1%. Familial clustering 
of SS has been reported but the level of evidence is low and limited to case 
studies[144]. The inflammatory myopathies are a group of rare diseases and genetic 
risk studies reveal both HLA and non-HLA associations however studies on familiar 
risk have not been published[145].  
The discordance between monozygotic twins in among the CTDs reinforces the idea 
that genetics alone is not responsible for the development of systemic autoimmune 
rheumatic disease. Many additional factors are likely to contribute including 
environmental exposures and random somatic events occurring in early embryonic 
development such as genomic imprinting or X chromosome inactivation that is 
recognised to result in phenotypic differences[143].  
2.3.3 The pre-clinical period: autoantibodies are detectable in SLE, SS, SSc 
and IM 
The period before clinical disease where abnormalities in immune function is 
detectable however signs and symptoms of tissue injury are absent has been 
defined as the ‘preclinical’ period[140]. In this stage of disease, genetic and 
environmental risk factors are thought to interact to initiate and propagate immune 
dysfunction which eventually evolves to a state of detectable tissue inflammation 
and damage[146, 147]. Increasing data support the existence of the preclinical 
phase across the range of CTDs which can be identified using biomarkers of 
autoimmunity and inflammation.  
2.3.3.1 Preclinical SLE 
Autoantibodies that characterise SLE are detectable in the serum of patients years 
before the onset of symptoms [148, 149]. A large prospective study of United States 
military personnel by Arbuckle et al demonstrated a high prevalence of preclinical 
ANA positivity at a titre of ≥1:120 in 78% of individuals with SLE at a mean of 
approximately 3 years before the clinical diagnosis. This compared with 0% ANA 
positivity at this level in matched healthy controls[131]. A remarkable observation in 
this study was the finding that the earliest sample was ANA positive in many cases, 
suggesting that the duration of preclinical autoimmunity exceeded the 3 year 
duration reported in this study. Indeed, SLE-associated autoantibodies have been 
reported >9 years prior to the diagnosis of classifiable SLE[150]. Arbuckle et al also 
showed that autoantibody specificities for ANA may materialise at different time 
points prior to the onset of SLE[131]. Autoantibodies against dsDNA, Smith, and 
RNP antigens were found to appear closer to the onset of SLE compared to 
autoantibodies against anti-phospholipid, anti-Ro/SSA and anti-La/SSB. The former 
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three autoantibodies were detected an average of 1 - 2 years prior to the onset of 
symptoms of SLE, compared with 2 - 3 years for ANA, anti-phospholipid, and anti-
Ro/SSA and anti-La/SSB autoantibodies[150]. Of all the autoantibodies, the anti-
RNP antibody demonstrated the shortest interval between positive testing and the 
onset of SLE symptoms and diagnosis, with duration intervals of 0.20±0.47 years 
and 0.88±0.32 years respectively. Compared with positive ANA testing, this interval 
was shorter by approximately 2 years and 2.5 years respectively.  
The evidence for evolving immune dysregulation in SLE has been further supported 
by Arbuckle et al through the finding of autoantibody specificity accrual in the lead 
up to SLE[131]. Arbuckle et al demonstrated an increase in the average number of 
autoantibody specificities prior to diagnosis, from 1.47 per person six years before 
diagnosis, to 2.58 at the onset of symptoms, and 3.01 at the time of diagnosis of 
SLE. The number of autoantibody specificities detected at SLE diagnosis appeared 
to remain static at 5 years. This suggests that SLE tends to arise in asymptomatic 
persons with accumulating positive immunologic tests, and that immunosuppression 
may halt the evolving immunodysregulation. 
Similar results have been reported by Eriksson et al who found that antibodies to 
Ro/SSA, RNP, histone, La, and dsDNA and ANA were detectable in 63% (n = 38) of 
patients with SLE approximately 4.2 years before the onset of the disease[150]. In 
this study, anti-Ro was detected first in the serum of these patients, 6.6 years before 
the onset of symptoms and 8.1 years before the diagnosis of SLE.   
2.3.3.2 Preclinical SSc 
A preclinical stage of autoimmunity has also been suggested for SSc. In this 
disease, the two most common autoantibody specificities are the anti-centromere 
(ACA) and the anti-topoisomerase I (anti-Scl70 Ab) which are highly specific for the 
diagnosis of SSc and are rarely found in healthy people[151]. The approximate 
sensitivity of these autoantibody subtypes is 30% and specificity is 99%[151]. It is 
known that these autoantibodies can precede the clinical signs of SSc in years. 
Raynaud phenomenon is usually the first manifestation of the disease and may 
antedate the onset of definite SSc by years[152]. The triad of Raynaud, SSc-specific 
autoantibodies, and SSc-specific nailfold capillaroscopic changes, even in the 
absence of other signs of definite SSc, identifies a subset of individuals at highest 
risk of progression to SSc, referred to as early SSc[153, 154]. Prospective studies of 
early SSc have reported a mean time interval of 4.6 ± 4.5 years from diagnosis of 
early SSc to evolution to classifiable SSc[153]. On multivariate analysis, Trapiella-
Martinez et al in a prospective study of early SSc identified digestive involvement as 
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an independent risk factor for the progression of early SSc to definite SSc with an 
OR of 17.0 (95% CI 6.1 - 47.2, p <0.001)[155].       
2.3.3.3 Preclinical SS 
The pre-clinical stage of SS is well-recognised. Anti-Ro and Anti-La autoantibodies 
are commonly found in the circulation of patients prior to SS. In addition, these 
antibodies appear in the serum of mothers who have given birth to babies with 
congenital heart block or neonatal lupus[148]. Most of these women are healthy 
however a proportion of mothers have been observed to go on to develop SS or 
SLE, in some cases several years after delivery[156, 157]. A small prospective 
study of women (n = 23) detected to be Ro or La autoantibody positive during 
pregnancy reported that two patients developed SS after a pre-clinical period of 5 - 9 
years[148]. In another cohort of pregnant women, almost all participants were 
shown to develop SS during a 9-year follow-up period (mean 4.5 years)[156]. Other 
longitudinal population studies have reported evidence of a preclinical phase in up to 
66% of patients with SS, based on the presence of ANA, Rheumatoid Factor (RF), 
anti-La or anti-Ro antibodies approximately 5 years before the onset of SS, and in 
some individuals up to 18 years before diagnosis of the condition[158]. This finding 
was confirmed in a more recent cohort study (n = 117)  of pre-clinical SS where 
autoantibodies were detectable up to 20 years (median 4.3 - 5.1 years) before the 
diagnosis of SS in 81% of patients, and for some cases possibly earlier, since the 
earliest sample analysed was positive[159]. The most common autoantibodies were 
ANAs followed by RF, anti-Ro60/SSA, anti-Ro52/SSA, and anti-La/SSB. Anti-
Ro60/SSA and anti-Ro52/SSA were found to have the highest positive predictive 
values of SS development, at 25% and 100% respectively.      
2.3.3.4 Preclinical IM 
The rarity and heterogeneity of the IMs makes investigation of the pre-clinical period 
of the IMs difficult to establish. Pre-clinical reports on the prevalence of 
asymptomatic myositis-specific and myositis-associated autoantibodies are lacking 
for this group of conditions. From a genetic perspective, there are few reports on the 
familiar occurrence of these diseases, hence the heritability of the inflammatory 
myopathies is unknown[92, 160, 161]. Higher prevalence of autoimmune rheumatic 
disease, such as SLE, autoimmune thyroid disease and type 1 diabetes mellitus 
have been reported in patients with IM, as well as in first-degree relatives of both 
adult and juvenile patients with IM[162, 163]. This aggregation of autoimmunity 
supports the idea that a shared genetic and/or environmental factor is responsible 
for the development of the condition. Infectious agents, physical exertion, 
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malignancy, bovine collagen implants and smoking have all been identified as 
possible environmental risk factors for IM, however the quality of evidence is low 
and based on small cohorts or case-control studies[92, 164]. Myositis-specific and 
myositis-associated autoantibodies however do show clear associations with distinct 
clinical phenotypes of IM, and disease prognosis, and serum titres have previously 
been shown to correlate with disease activity which suggests a direct pathogenic 
role of the autoantibodies[165]. MSAs and MAAs furthermore are highly specific and 
rarely are detectable in healthy subjects. In one small study, the reported range of 
specificity for IM for the MSA/MMA antibody panel was 76 - 100%, with the highest 
specificity found for anti-Jo-1, anti-PL-7, anti-PL-12, and anti-PM/Scl[166]. This 
compares with a detection rate of MSA/MAAs in 4% of healthy sex- and aged-
matched subjects (n = 2/50) and 39% of similarly-matched disease controls who 
represented various rheumatic and muscle disorders (n = 70). Importantly, in this 
study, the control group were mostly positive for the Ro52 antibody which is 
recognised for its low specificity across the spectrum of autoimmune rheumatic 
diseases. This data collectively suggests a direct pathogenic role for the MSA/MMA 
autoantibodies and a probable short period of preclinical autoimmunity 
2.3.4 The risk of benign autoimmunity 
As discussed earlier in this chapter, ANAs are detectable in a considerable 
proportion of the general population, and despite an association with an increased 
risk of CTD, are on their own insufficient to lead to the development of autoimmune 
rheumatic disease[167-169]. The overall prevalence of ANA in the general 
population is estimated at 13.8% (95% CI 12.2 - 15.5%) and rises in prevalence with 
older age, female gender, chronic infections and chronic medical morbidities[170]. 
Healthy relatives of individuals with autoimmune rheumatic disease are also 
recognised to have high rates of asymptomatic autoantibody positivity, which 
supports the idea of a shared environmental and genetic origin in the development 
of immune aberrancies[171]. The prevalence of systemic autoimmune rheumatic 
disease in the community however is lower in comparison at approximately 0.1%, 
and rises to 1% in women over the age of 45 years[172] . The overall odds of 
development of autoimmune rheumatic disease in an individual with antinuclear 
autoantibodies is estimated between 10- to 30-fold[150]. The discrepancy between 
autoantibody positivity and the onset of autoimmune rheumatic disease suggests 
that immune dysfunction is an evolving process and that environmental and genetic 
interactions play an important role.   
Some authors consider the state of asymptomatic ANA detection to be indicative of 
early autoimmunity or “preclinical disease”, and have used the term “benign 
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autoimmunity” to describe this stage of early immune dysfunction[173]. During this 
stage, genetic and environmental risk factors are assumed to interact to initiate and 
propagate the development of autoimmunity, resulting in detectable tissue 
inflammation and injury in select individuals. Autoantibodies are markers for 
autoreactive B cells and plasma cells. Autoantibodies have the ability to form 
immune complexes and/or participate in auto-antigen presentation which is the initial 
phase of innate and adaptive immune system activation and autoimmune disease. 
An unaddressed question in the concept of benign autoimmunity however is when 
and how does it become pathogenic? Recent data suggests that benign 
autoimmunity in itself is a risk factor in cardiovascular disease (CVD) 
development[173]. 
2.3.4.1 Preclinical autoimmunity: a risk factor for cardiovascular disease? 
Individuals with systemic autoimmune rheumatic disease have a higher risk of 
cardiovascular disease. This is well-established in RA where the risk is 1.5 to 2 fold 
and comparable with the risk in type II diabetes mellitus[174, 175]. RA-related 
autoantibody positivity has been associated with an increased prevalence of CVD 
events in patients with RA, and antibodies to anti-cyclic citrullinated peptide have 
been correlated with carotid intima media thickness in early RA[176-178].  
In SLE, CVD is the leading cause for mortality[179]. The spectrum of anti-
phospholipid antibodies have been correlated with an increased risk of 
cardiovascular events and subclinical atherosclerosis in patients with SLE. In one 
large US prospective study, the prevalence of MI in lupus anticoagulant-positive 
SLE patients was reported at 22% compared with 9% (p=0.04) in non-positive 
patients[180]. In 182 Swedish patients with SLE, the presence of either the anti-
cardiolipin or anti-beta2 glycoprotein antibody was strongly associated with an 
increased risk of first CVD event (HR 4.9, 95% CI 1.76 - 17.72)[181].This finding 
was confirmed in a follow-up study of 208 patients in the same inclusion cohort over 
12 years, where the auto-antibodies were predictive of cardiovascular mortality (HR 
2.8, 95% CI 1.1 - 1.7)[182]. Levels of anti-cardiolipin antibody and anti-beta2 
glycoprotein have been correlated with myocardial perfusion defects in SLE 
patients, as detected by single-photon emission computed tomography, 
Interestingly, the defects were not within the distribution of the major coronary 
arteries, suggesting that the auto-antibodies may contribute to microvascular 
thrombi in the cardiac microcirculation[183]. Recently, An increased risk of coronary 
artery calcification, a marker of overall atherosclerotic burden, was reported in 
patients with SLE and antiphospholipid antibodies in two separate studies[184, 185]. 
In contrast, anti-Smith, anti-dsDNA, and anti-RNP have shown positive correlations 
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with cardiovascular disease in SLE, however did not reach statistical 
significance[181].  
An increased rate of CVD events has been reported in patients once considered to 
have had benign autoimmunity to suggest a pathogenic role for the auto-antibodies 
beyond clinical autoimmune rheumatic disease. This has been demonstrated in 
several large pre-clinical RA studies where both RF positivity and anti-CCP positivity 
have been associated with an increased risk of ischaemic heart disease and CVD 
mortality[186-190]. There is a growing number of studies to demonstrate the same 
association in pre-clinical CTDs. Positivity for ANA without autoimmune rheumatic 
disease has been associated with increased rates of triple-vessel coronary artery 
disease (OR 11.67, 95% CI 3.91 - 17.82)[191], and increased risk of myocardial 
infarction (HR 1.29 95% CI 1.03 - 1.61)[187]. Several studies have demonstrated a 
clear association between pre-clinical antiphospholipid antibodies and increased 
cardiovascular events[192-199]. The autoantibodies have been detected in the 
serum and plaques of pre-clinical cases, and have shown positive correlations with 
coronary intima media thickness and acute myocardial infarction[194, 200, 201]. 
Although one pre-clinical study drew a negative association between anti-
phospholipid antibodies and coronary arterial calcification, the association has been 
reported in subgroup analysis of the CARDIA (Coronary artery risk development in 
young adults) study[196]. Antiphospholipid antibodies were associated with 
subclinical coronary arterial sclerosis in African-American and white young adults 
after 15 years follow-up, with anti-β2GP1 IgG OR 6.4 (95% CI 2.4–16.8); anti- 
β2GP1 IgA: OR 5.6 (95% CI 2.3–13.2), anti-β2GPI IgM OR 1.7 (95% CI 1.0–3.1), 
and aCL IgG OR 5.1 (95% CI 1.4–18.6)[190].  
Associations between autoantibodies and subclinical and clinical atherosclerosis in 
individuals with and without rheumatic disease suggests a model in which pre-
clinical autoantibodies are not only a risk factor for rheumatic disease, but also for 
CVD, which may even develop in parallel with the condition. The proposed 
mechanisms are considered to be subclinical inflammation and non-thrombotic 
functions of antiphospholipid antibodies such as aberrant oxidisation of lipoprotein 
molecules and triggering of foam cell formation[202, 203]. There is a paucity of 
published data on this issue in preclinical SS, SSc and IM, making it an area of 
research need.          
2.3.5 Environmental factors in preclinical autoimmunity 
Genetic and environmental factors are thought to interact to progress the pre-clinical 
state of autoimmunity to a state of overt tissue damage and connective tissue 
disease. The prior subsection discussed the evidence for genetic contributions to 
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this process. This subsection will discuss the evidence for environmental factors in 
the instigation and progression of the preclinical state. Most of the known 
environmental factors have been identified through case control and cohort studies 
and there are no data that quantify the relative contributions of these environmental 
risk factors to disease development[204]. The environmental risk factors will be 
discussed according to the subset of preclinical disease.  
2.3.5.1 Environmental factors in preclinical SLE 
Various environmental factors have been implicated in the induction and 
acceleration of SLE. New theory in the model of autoimmune development in SLE 
holds that the first hit or initial break in tolerance may originate at the epithelial 
surface[147]. A strong body of evidence is available for RA for this process, which is 
beyond the remittance of discussion in this thesis, however, the evidence is growing 
in the CTDs. In RA, the mucosal surfaces have been identified as the primary 
initiating site, namely the lung, oral mucosa, and gut mucosa. In contrast, in the 
CTDs, the skin is postulated to be a primary initiating site.  
Ultraviolent (UV) light is an established trigger of SLE and SLE activity. 
Experimental studies have shown a significant immunomodulatory role for UV 
radiation and evidence of induction of SSA/Ro60 and anti-dsDNA 
autoantibodies[205-211]. UV light in proposed models of SLE is postulated to induce 
apoptosis and immune interaction of keratinocytes in the skin[208, 212]. Apoptotic 
keratinocytes express nuclear material in apoptotic blebs which have the ability to 
enter the circulation as microparticles. Circulating particles of nuclear material are 
thought to stimulate the expression of autoantibodies against ANA and activate 
innate and adaptive autoimmunity[147]. The site and sequence of events in this 
model however have not been subject to prospective study. It is supported by 
observations that cutaneous disease is one of the most common features of 
SLE[213]. In the skin of lupus patients photo-provocation by UV light has been 
shown to increase numbers of apoptotic keratinocytes compared to healthy 
controls[208]. Keratinocytes activated by UV light have also been shown to produce 
damage-associated molecular patterns (DAMPs) and inflammatory mediators that 
lead to the recruitment of lymphocytes and antigen-presenting cells, including 
peripheral dendritic cells.  
The gastrointestinal interface has been implicated in the pathogenesis of  CTD. The 
relationship is still not well-characterised. Two small studies have demonstrated a 
low Firmicutes/Bacteriodes ratio in patients with SLE compared with healthy 
controls[214, 215]. In murine lupus models Zhang et al 2014 reported marked 
depletion of Lactobacilli and an increase in Lachnospiraceae and Clostridiaceae 
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during the phase of lupus progression[216]. Dietary introduction of Retinoic acid 
(Vitamin A) restored the down-regulated Lactobacilli, and this correlated within an 
improvement in disease control[216]. Lactobacillus reuteri supplementation in the 
diets of mouse models of SLE has also been shown to prevent progression to 
lupus[216]. Levels of T regulatory cells were observed to be impaired within the pre-
supplementation model, and it was postulated that administration of Lactobacilli was 
protective due modification of the gut microbiota composition that favoured T 
regulatory cell induction. A decrease in regulatory T cells suggests a skewing in 
inflammatory and regulatory immune mechanisms which promotes disease 
development[217]. While the data supports a cause-and-effect model between the 
gut microbiota and SLE, more work is needed to fully understand the connection. 
Future research efforts should include therapeutic studies in human subjects.   
Dietary and nutritional factors have been proposed to play a role in the development 
of SLE[218-220]. Vitamin D deficiency has been associated with autoreactive 
immune abnormalities in healthy individuals, and the onset of SLE[221]. This is 
supported by epidemiological studies which identify high rates of Vitamin D 
deficiency in cohorts of undifferentiated CTD and SLE[221-228]. Alcohol 
consumption has been correlated with an increased risk of SLE in genetically 
susceptible individuals[229]. As a subject of controversy, alcohol has been shown to 
have a protective effect when used in moderation[230]. There have been no studies 
to date that correlate how alcohol affects the gut microbiota in models of 
autoimmune disease.  
Cigarette smoking and environmental air pollutants including the use of marijuana 
has also been shown to be a risk factor in the onset of SLE[229-237]. The biological 
effects of cigarette smoke are thought to arise from effects on HLA-DR3 alleles[238]. 
Silica as well as industrial pollution and solvents have also shown this 
association[239-244]. 
Several viruses have been proposed as factors that influence the development and 
progression of pre-clinical lupus[245-247]. EBV has been shown to induce the 
formation of ANA autoantibodies[248-250].  EBV and other viral antigens are 
thought to promote the generation of an initial autoimmune response and antibodies 
against nuclear antigens like SSA/Ro60[251], SmD1[252] and SmB0/B[250] through 
molecular mimicry[253, 254] and innate immune activation, which is then amplified 
through epitope spreading and positive feedback systems[251, 255]. 
Cytomegalovirus (CMV), retroviruses, human T-lymphocytic virus type 1, human 
herpesvirus-7, herpes simplex virus 2, hepatitis C, BK virus and parvovirus have 
also been implicated in the onset of SLE[140, 245-247, 256].  
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On the converse, some infectious agents have been reported to be protective 
against the development of SLE and arrest progression towards severe forms of the 
disease. This may be related to the ‘hygiene hypothesis’ and could explain the 
greater incidence of autoimmune disease in developed countries where higher 
hygiene standards and systems are in operation[257]. Helicobacter pylori was 
associated with a lower risk of early onset SLE in African Americans[258]. Hepatitis 
B virus was identified as a protective factor in Chinese SLE patients who were found 
to have a lower prevalence compared to healthy controls[257]. In murine models of 
SLE, a decreased disease severity was observed in mice infected with Toxoplasma 
gondii[259], Plasmodium chabaudi[260], and lactate dehydrogenase elevating 
virus[261].  
Medications have an established connection with the induction of CTD[262]. 
Although the evidence is limited to case reports and cohort series, drug-induced 
forms of SLE, SS, SSc and IM have been recognised and may be managed through 
withdrawal of the offending drug. Environmental factors in preclinical SS 
Infectious agents, particularly viruses, have been considered to be involved in the 
priming or triggering of SS[263]. It is thought that viruses promote autoantibody 
production through a process of molecular mimicry that leads to epitope spreading. 
EBV, CMV, chronic Hepatitis C, human T-cell leukaemia virus, and coxsackieviruses 
are commonly implicated in the pathogenesis on pSS, based on reports of viral 
antigen detection in the saliva or glandular biopsies of humans and animal 
models[264-268]. Re-activation of EBV and CMV has been suggested in the 
induction and maintenance of the disease[267, 269]. Defective viral clearance from 
salivary gland epithelial cells is postulated to lead to viral persistence, chronic 
lymphocytic sialadenitis and subsequent glandular dysfunction[270, 271]. Infection 
of C57BL/6-lpr/lpr mice with murine CMV resulted in sialadenitis which persisted 
after clearance of the virus and was associated with high levels of anti-Ro, anti-La, 
RF and dsDNA autoantibodies[272]. A different group reported similar outcomes 
with CMV-infected NZM2338 mice[273].  
Foreign antigen immunisation with components of the Ro/La particle has been 
reported by several groups to trigger the onset of SS in murine models[274, 275], 
with reports of epitope spreading. An illness similar to SS was reported in BALB/c 
mice immunised with short peptides from the sequence of the 60 kD Ro 
antigen[276]. The mice were observed to develop salivary gland lymphocytic 
infiltrates and salivary gland dysfunction. The investigators applied the same 
protocol in different mouse strains and observed differences in the development of 
SS. Development of the disease was interrupted at different stages, ranging from 
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immune response to the peptide, epitopes spreading, systemic autoimmunity and 
lymphocytic infiltration of the salivary glands, to dysfunction of the gland. This study 
highlights the role of genetics in the overall pathway of disease pathogenesis, 
suggesting genetic control in immune reactivity, epitope spreading, and disease 
manifestations[277]. 
Cigarette smoking has been demonstrated to be a risk factor for pSS-associated ILD 
(OR 12.84, 95% CI 1.71 - 96.53)[278]. A large cross-sectional multicentre study 
conducted identified that the risk of pSS  was significantly associated with a high 
cumulative occupation exposure to toluene (OR 4.69, 95% CI 1.42–15.45), white 
spirit (OR 3.30, 95%CI 1.07–10.26), aromatic solvents (OR 2.50, 95%CI 1.06–5.91) 
and any types of solvents (OR 2.25, 95% CI 1.20–4.22)[279]. 
Oestrogen deficiency has been correlated with the development of pSS, and may 
explain the predominance of the disease in women.  Aromatase gene inactivated 
mice modelled for oestrogen deficiency were reported to develop autoimmune 
disease resembling SS[280]. In another study, retinoblastoma-associated protein 48 
transgenic mice were found to develop glandular dysfunction only in conditions of 
deficiency in oestrogen[281]. Human cohort studies are conflicting on the 
association of sex hormones and SS[282]. The data at present is circumstantial and 
more needs to be undertaken before a clear association can be made. 
2.3.5.2 Environmental factors in preclinical SSc 
A spectrum of inciting stimuli have been associated with the onset of SSc[283]. 
Chemical agents have been the most cited environmental factors in SSc 
development, and includes silica, solvents, silicone breast implants, epoxy resins, 
welding fumes, pesticides and hair dyes[284]. Several occupations are recognised 
to be at higher risk of SSc due to higher contact intensity[284]. A scleroderma-like 
disorder has been described following exposure to bleomycin, a chemotherapeutic 
agent often administer in cancer[285]. In rat and mice models, infiltration of 
bleomycin into the lungs was observed to lead to the development of fibrosis in a 
dose-dependent manner[286-288]. Many other drugs have been associated with the 
onset of SSc[283]. Moreover, several reports have described the occurrence of 
pregnancy-related SSc. It is postulated that foetal cells enter the maternal circulation 
through placental transfer and induce a graft-versus-host reaction with likeness to 
SSc in the mother[289, 290]. This is theory is supported by reports of the detection 
of foetal DNA and cells in the peripheral blood and skin biopsies of women with SSc, 
in some cases years following the puerperium[289, 291, 292]. However robust 
evidence of a mechanistic role of foetal-to maternal antigenic transfer in the 
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pathogenesis of SSc is lacking, and the theory would not explain the occurrence of 
SSc in men or nulliparous women.   
2.3.5.3 Environmental factors in preclinical IM 
Alike other autoimmune diseases, the environmental risk factors of IM have been 
identified from animal models, case reports and/or case series; and seem to vary 
between phenotypes of IM[92]. Associations have been made with several viral[293-
300], bacterial and parasitic infections[301], UV radiation[302, 303], smoking[92, 
304], collagen and silicone implants[305, 306], birth date[307], seasonal 
variations[307, 308], occupation exposures to gases, dust and fumes[309], and an 
expansive list of chemical and drug agents and dietary supplements[92]. Case 
reports and animal models have identified several specific possible infectious 
triggers of IM. These include hepatitis B virus (DM[294], PM[293]), hepatitis C virus 
(IBM[295]); retroviruses such as HIV and human T-lymphotrophic virus-1 (PM[296], 
DM[297], IBM[298, 299]), influenza, picornavirus, echovirus (DM, PM), and 
Toxoplasma and Borrelia spp[300, 301] (DM, PM). A multitude of drugs have been 
reported as possible causative agents, including D-penicillamine, an older style for 
RA drug now rarely used[310], and statins, a drug often associated with necrotising 
myopathy[311] and the induction of anti-HMGCR antibodies[312], however reported 
to initiate the onset of DM and PM[311]. Systemic and localised forms of IM have 
been associated with vaccination based on animal studies and case reports [313]. 
This has plausibility given that the risk of IM seems to be increased after any 
infection (OR 1.5, 95% CI 1.2 - 1.9), especially gastrointestinal (OR 1.9, 95% CI 1.1 
- 3.5) and lower respiratory tract infections (OR 2.3, 95% CI 1.8 - 3.3), with the 
exception of DM/PM where it appears to be decreased following upper respiratory 
infections according to epidemiological studies[314]. One epidemiological study 
however reported no association between vaccines and PM and DM[315]. In 
contrast to the aetiological theory of infectious initiation of IM, parvovirus appeared 
to be protective against the occurrence of juvenile DM (OR 0.35, 95% CI 0.14 - 0.9). 
The epidemiological literature identifies an increased risk of DM and PM after 
excessive physical exertion (OR 3.9, 95% CI 1.8 - 8.2)[315]; tobacco is a risk factor 
for anti-Jo1-related IM (OR 3.94, 95% CI 1.54 - 9.89)[316]; bovine collagen dental 
implants (OR 5.05, 95% CI 2.31 - 9.59) are linked with DM[305]; and group A 
streptococcal infections have been associated with juvenile DM (OR 2.73, 95% CI 
1.14 - 6.53)[317]. Maternal exposure to air pollution, smoking, and occupational 
dusts and solvents have been raised in a small study to have potential associations 




2.3.5.4 Defining nomenclature in preclinical CTD 
There is a growing effort to develop methodical terminology to describe the various 
stages of the pre-classification period of CTD[140, 318, 319]. Authors have 
motioned for terminology that can distinguish individuals at every stage of 
development within the CTD continuum. This includes individuals with increased 
genetic and environmental risk (high-risk for CTD), pre-clinical autoimmunity and 
immune dysfunction (pre-clinical CTD), early forms of CTD (incomplete CTD), fully 
developed but non-classifiable CTD (unclassifiable CTD), and classifiable CTD. 
Terminology is further required to distinguish between individuals who are high-risk 
versus low-risk for disease progression during the pre-clinical period. Some terms 
introduced into the literature are misleading due to lack of broad descriptive 
characteristics. Terms such as “pre-clinical SLE” are misleading since many 
individuals with features of SLE do not go on to develop lupus[320]. Other terms 
such as for example “latent SLE”, “probable SS”, “evolving IM” and “incomplete SSc” 
raise similar bias and confusion, and are increasingly disregarded in favour of more 
neutral terms such as UCTD or “at risk” of CTD. These terms are broad enough to 
describe the disease manifestations suggestive of CTD however do not commit to a 
definitive diagnosis. This is particularly important given that the first three years of 
autoimmune disease are often marked by transient or developing disease features.  
2.3.6 Problems with ANA testing 
ANA positivity is common in the general population, and while the actual frequency 
of positive assays varies with methodology, about 20% of individuals in 
epidemiology studies express borderline levels, corresponding to 
immunofluorescence titres of 1:40 titres or greater[169, 321, 322]. This figure 
decreases to 5% at significantly elevated titres of 1:160 and 3.3% at 1:320[323, 
324]. The basis of this seropositivity is unclear. ANAs are present in nearly all cases 
of diagnosed disease of CTD. However ANA positivity is neither specific nor 
prognostic, because most individuals with these antibodies will never develop an 
autoimmune disease. Indeed the dense fine speckled pattern of nuclear 
fluorescence (anti-DFS), which corresponds to autoantibodies targeting the dense 
fine speckled 70kDa protein, has been reported in approximately 9% of healthy 
individuals and has been proposed as a marker against the presence of 
autoimmunity[325]. However the autoantibody has been detected in up to 3% of 
patients with SLE and in patients with Hashimoto’s thyroiditis. This raises doubts 
regarding the reliability of anti-DFS as a negative of biomarker ANA-associated 
autoimmune disease, or autoreactivity in general, given the evidence of association 
with definite autoimmune disease.    
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Epidemiological studies profile ANA positivity at titres of 1:40 or greater to be most 
prevalent within the female gender[326]. Associations between the presence of ANA 
and age are less well described, however are highest in those aged 40-49 years, at 
least according to one study[170]. Other studies have reported increasing 
prevalence of ANA expression with age (p = 0.01), with the highest levels seen in 
individuals aged >70 years[327]. However other studies have shown no correlation 
between ANA positivity and age[328].  
Ethnic associations with ANA expression have also been examined in 
epidemiological studies. Higher prevalence has been reported in the non-Hispanic 
black population[170] and in African American[169] individuals compared with other 
ethnic groups. As higher rates of SLE are found in these population, this relationship 
is suggestive of a link between the development of autoantibodies in health and the 
development of CTD[329]. The same link applies to the associations observed for 
the female gender, where SLE constitutes 80 - 90% of patients with SLE[330].  
It is possible that these results represent limitations of ANA assays and the 
detection of either low titre or low avidity autoantibodies which may never cause 
autoimmunity[322]. Alternatively, it may represent cross-reactivity with other non-
nuclear antigens[322]. This is becoming less of an issue due to the increasing use of 
automated solid phase multiplex assays, which are less sensitive but generate more 
false-negative results[322, 331]. It is beyond the scope of this thesis however for this 
reason the immunofluorescence Hep-2 (human epithelial cells) platform has been 
recommended by an ACR taskforce as the preferred ANA screening method over 
direct assays[332].   
Another explanation for the frequency in ANA expression in the general population 
may relate to intrinsic derangements in immune function[322]. ANA positivity in 
healthy individuals may represent the beginnings of subclinical autoimmunity, as 
previously discussed in Chapter 2.3.3, although this could be debated, given that 
one study showed greater lupus-related gene upregulation in some healthy 
individuals who were ANA negative than in those who were ANA positive [322, 328]. 
Further work is needed to identify the determinants of disease progression in ANA-
related rheumatic diseases, and the relationship between gene expression, serology 
and disease[322]. This would be particularly valuable to the effort put forward to 
reduce unnecessary ANA testing and relieve healthcare costs[333].        
2.3.7 Biomarkers in CTD 
Biomarker research is an area of increasing interest in CTD. A biomarker is defined 
as a measurement whose alterations correlate with the pathogenesis and/or 
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manifestations of a disease and can be evaluated through quantitative or qualitative 
methods in laboratories[19]. It can include, but not have limitation to, a genetic, 
biological, biochemical, molecular or imaging event. Biomarkers can be prognostic, 
diagnostic, predictive, pharmacodynamic and surrogate[19]. Prognostic biomarkers 
identify a specific disease feature, individuals at risk of a disease, or those likely to 
experience future disease activity[19]. Diagnostic biomarkers confirm the presence 
or subtype of a disease. Predictive biomarkers are used to anticipate therapeutic 
response[19]. Pharmacodynamic biomarkers guide therapeutic drug dosing. 
Surrogate biomarkers are substitutes for clinical end points[19].    
Many biomarkers have been identified for CTD however no single biomarker has 
emerged as surrogate for disease activity or the prediction of disease[18, 19, 334]. 
Biomarkers have included cell surface proteins, autoantibodies, cytokines, and 
protein components of the immune system[19, 20]. Double-stranded DNA and 
complement are routine clinical diagnostic and predictive biomarkers for SLE and 
compromise components of disease activity indices[19]. Elevation in dsDNA 
autoantibodies correlate with the onset, activity and impending activity of SLE and 
LN[18, 19]. Low complement system C1q, C3 and C4 has shown similar correlative 
ability in terms of SLE activity and flare prediction[19]. Other rheumatological 
diseases, malignancies, infections and endocrine disorders however can influence 
either biomarker and sometimes the biomarker is not featured and/or a reactive 
component of an individual’s lupus disease[19]. Although in routine use, dsDNA 
autoantibodies and complement are not universal features of lupus and so their 
application is limited within the lupus population[19]. 
Emerging biomarkers in lupus are established on cell signalling pathways and 
involve cytokines, chemokines, growth factors and acute phase reactants[19]. These 
include serum IFN-alpha, BLyS/BAFF, APRIL, TNF-alpha, IL-6, IL-12, IL-21, IL-23, 
IL-1, IL-17, TGF-beta, urinary TWEAK, Axl, Fas, ferritin, insulin-like growth factor 
binding protein 2 (IGFBP-2), insulin-like growth factor binding protein 4 (IGFBP-4), 
sialic acid-binding Ig-like lectin 5 (siglec-5), anti-mutated citrullinated vimentin 
antibody (anti-MCV), erythrocyte-bound C4d (E-C4d), B cell bound C4d (B-C4d), 
Vascular cell adhesion molecule-1, monocyte chemoattractant protein-1 (MCP-1) 
and sTNFRII[18, 19, 334]. BLyS (also known as B cell activating factor or BAFF) is a 
B cell growth and survival promoter and has been correlated with SLE disease 
activity, serum immunoglobulin and dsDNA levels. Manifestations of discoid rash, 
renal disease, serositis and lymphopaenia have been associated with elevated 
levels of BLyS however the biomarker failed in longitudinal studies to correlate with 
disease flare[19, 20]. Despite molecular similarities to BLyS, a proliferation-Inducing 
ligand (APRIL) negatively correlated with lupus disease activity and anti-dsDNA 
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levels[18, 19]. APRIL also showed no significant inability to discriminate between 
pre-flare and non-flaring SLE[18, 19].  
TNF-alpha, a cytokine with B cell regulation and T cell stimulation properties, has 
traditional associations with drug-induced lupus and dsDNA antibody induction when 
blockaded by TNF-alpha inhibitors[18, 19]. Conversely, high serum TNF-alpha has 
been shown to correlate with flares and activity in lupus subjects. IL-6, a pro-
inflammatory cytokine, has been demonstrated to correlate with lupus diagnosis, 
activity and impending activity[18, 19]. Raised serum IL-12 and IL-23 cytokines have 
correlated with SLE diagnosis and higher levels have been demonstrated in pre-
flare SLE compared to no-flare SLE[18, 19]. Serum IL-23 was also associated with 
proliferative LN and renal lupus activity[18, 19]. Serum IL-1 is higher in SLE patients 
and active SLE patients compared to healthy controls[18, 19].  
TGF-beta is a fibrotic cytokine involved in would healing and angiogenesis[18, 19]. 
Elevated urinary TGF-beta mRNA levels were higher in diffuse proliferative LN and 
reduced in LN patients responsive to therapy[18, 19]. IL-21 is a pro-inflammatory 
cytokine that influences the generation of autoantibody-secreting plasma cells. 
Increased IL-21-producting peripheral CD4+ T cells in SLE correlate with a 
concurrent increase in memory B cells and Th17 cells and reduced Treg cells[18, 
19]. IL-17 is a pro-inflammatory Th cellular pathway cytokine and has been 
correlated with disease activity in non-renal and renal SLE patients and pre-flare 
SLE verses no-flare SLE[18, 19].  
IGFBP-2 showed higher levels in LN, and correlation with disease activity and 
clinical and histological response[18, 19]. Axl, sTNFRII, ferritin and IGFBP-2 strongly 
correlated with active SLE compared to inactive SLE and healthy controls[18, 19]. 
IGFBP-4, a biomarker of diabetic nephropathy, was shown to be detectable at 
increased levels in LN patients compared with non-lupus renal disease and healthy 
controls[18, 19].  
TNF-like weak inducer of apoptosis (TWEAK) is a member of the TNF family 
capable of inducing IL secretion, apoptosis and cell differentiation[18, 19]. Urinary 
TWEAK correlated with disease activity in LN. MCP-1 is a recruiter of monocytes, 
memory T lymphocytes and NK cells to inflammatory sites. LN patients compared 
with patients without LN and HC showed higher levels of serum MCP-1 and urinary 
MCP-1 which correlated with flares, urine protein and response to treatment[18, 19]. 
Neutrophil gelatinase-associated lipocalcin (NGAL) is released from following renal 
injury and inflammation[18, 19]. Levels are higher in SLE patients with LN than in 
SLE patients without LN and are correlated with disease activity. Urinary neutrophil 
gelatinase-associated lipocalcin levels correlated with renal flares if elevated on a 
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proceeding visit. Vascular cell adhesion molecule-1 is central to immune cell 
recruitment into tissues. Increased levels correlate with SLE disease activity and 
active LN compared with non-renal and inactive SLE[18, 19].  
Similarly, for SSc, SS and IM clinical and research biomarkers are under increasing 
attention. ANA autoantibody specificities are central to clinical practice and are 
prognostic and diagnostic biomarkers in their own right for each of the CTDs[90, 
111, 149, 204, 332]. In SSc, there are a wide range of candidate biomarkers under 
evaluation, including circulating miRNA, proteins derived from collagen and the 
extracellular matrix, markers of angiogenesis and end-organ damage, and many 
cytokines, chemokines and growth factors[326]. Scleroderma-affected skin has been 
subject to biomarker exploration using gene expression and cytokine profiling[27, 
74, 153, 155, 335]. In SS, a more restricted range of biomarkers are under 
investigation in serum, saliva and tears[56, 60, 64, 72, 159, 326]. A particular focus 
has been on markers of B cell function and activity in SS given their central role in 
disease pathogenesis[56, 59, 62-64, 66, 72, 158, 273, 281, 336]. In DM, PM and 
IBM candidate biomarkers include microRNA, chemokine, cell subset and cytokine 
assays of the serum, muscle, lung and skin[88, 90, 91, 96, 161, 164, 165, 312, 316, 
326, 337].  
The emerging list of biomarkers have been identified through cross-sectional studies 
and/or small patient cohorts and require validation in larger cohorts before their 
clinical role is established[18, 19]. Given the heterogeneous nature of CTD, it is not 
unexpected for some of these biomarkers to yield conflicting results or fail to fulfil 
their potential within validation studies[18, 19]. For example, in SLE, drug studies 
have identified a dichotomy between patients in terms of IFN status (i.e. high/low), 
which may influence response to IFN-blocking therapy[338, 339]. This concept has 
led some biomarker researchers to propose the development of composite 
biomarker panels to overcome this issue of immune dysfunction heterogeneity within 
and between CTD subsets[18, 19]. To date no validated biomarker panel however 
has gained widespread use in clinical settings, which is probably a reflection of their 
cost and processing demands[18, 19]. Interferon however has gained increasing 
interest as a biomarker in CTD and will be discussed further in the next 
subheading[20].  
2.3.8 Interferon 
Interferons (IFNs) are a group of intercellular signalling proteins that have antiviral, 
immunomodulatory and anti-tumour properties [340, 341]. There are three subtypes 
of interferons: type I, type II and type III IFN[342]. The classification of IFN is based 
on differences in receptor binding, molecular structure and source of cellular 
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production[342]. The type I IFN (IFN-I) family includes IFN-α, IFN-β, IFN-ε, IFN-κ 
and IFN-ω and bind to a single receptor, INF-α receptor (IFNAR)[343]. Type II and 
type III IFN includes IFN-γ and IFN-λ respectively[342].  
Although many types of cells can produce IFN, the primary source of IFN-I appears 
to be the pDCs[22, 344]. pDCs uptake immune complexes containing DNA/RNA 
through the Fc-γ receptor IIA and in turn express type I IFNs through the activation 
of intracellular nucleic acid-sensing TLRs[345]. Dysregulation of the IFN-I pathway 
has a well-established role in the pathogenesis and activity of multiple autoimmune 
diseases and is of increased interest due to evidence that it may define clinical 
phenotypes as well as the potential to respond to IFN-blocking therapy[20, 340].  
A central pathogenic role for IFN-I has been established across the entire CTD 
spectrum. In lupus, serum IFN-I assays have been correlated with disease flares 
and serological and clinical features[20]. This includes neuropsychiatric disease, 
histological severity in glomerulonephritis, fever, rash, arthralgia and 
leukopaenia[346-351]. Smaller studies have reported correlations between IFN 
expression, disease flares and severe lupus features (e.g. internal organ 
involvement)[352]. A recent prospective study determined that IFN assays were 
predictive of progression to CTD in a preclinical cohort[25]. Besides SLE, 
upregulation of IFN-I has been detected in the peripheral blood cells of patients with 
pSS, DM, PM, RA, MCTD and SSc and positively correlated with disease activity in 
DM, PM, RA, pSS and SSc [335, 336, 353-357]. This includes lung fibrosis, digital 
ulcers and digital loss in SSc [358]. Myositis in DM and PM with concordant 
decrease in IFN expression following immunomodulatory therapy and disease 
regression[337]. Complement and hypergammaglobulinaemia (but not other 
ESSDAI domains) in pSS[357]. Over-expression of IFN-I has also been observed in 
the skin and synovial tissue of patients with lupus, labial salivary biopsies of patients 
with pSS, muscle of patients with IM, skin of patients with scleroderma, and 
positively correlated with peripheral IFN blood levels [22, 354, 358-366]. Positive 
correlations have also been made with anti-dsDNA and ENA antibodies, 
hypocomplementaemia and elevated serum BAFF[344]. 
A major barrier in the characterisation of IFN-I activity is the reliability of current IFN 
measurement systems [19]. IFN molecules measured directly in serum or plasma 
can be intermittent due to localised expression and uptake, or very low and hard to 
detect[19]. IFN-stimulated gene expression (ISGs) (known as IFN signatures) and 
weighted IFN-inducible gene scoring systems (known as IFN scores) are alternative 
methods of determining IFN expression [343]. IFN signatures represent the 
detection of pre-determined sets of ISGs and yield an output of “high” or “low” 
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expression (qualitative)[24]. IFN scores refer to a continuous parameter of ISG 
transcriptional activity as derived from quantitative PCR detection[20].  
While IFN-I signatures and scores have been shown to correlate with disease 
features and flare risk in many cross-sectional studies, results are inconsistent and 
have received negative validation in longitudinal studies[367-369]. Given over 100 
genes are induced during type I IFN pathway activation, differences in ISG selection 
and weighing are likely to account for the performance differences among the IFN 
signatures and scores[368]. Contribution of type-II or type III IFN and other non-IFN 
cytokines to the IFN-I signature; ethnicity, the pathogenic heterogeneity of lupus, 
and the limitations of data-reduction in gene selection are additional confounders in 
these results[25]. Gene expression may also vary between circulating cell 
populations such that assays that use whole blood or unsorted PBMCs may show 
apparent differences in level of ISG expression[25]. Changes in the size of cell 
populations may also influence results; for example, leucopaenia as is characteristic 
of autoimmune disease and when transient during autoimmune activity[25]. 
This complex relationship may be addressed through the alternative investigation of 
non-gene-based surrogate markers of IFN-I, such as interferon-induced proteins 
(e.g. IFIT4) and chemokines (e.g. CCL2, CXCL10)[370, 371]. Tetherin, an 
interferon-induced anti-viral membrane protein, has a physiological role in inhibiting 
enveloped viral particle release from the surface of infected cells[372]. Associations 
have been shown between serum flow cytometric tetherin and lupus severity and 
activity[373]. As a flow cytometric biomarker tetherin has convenience in terms of 
negating the need for complex RNA extraction and analysis. 
Given its role in disease pathogenesis, blockade of IFN-I has the potential to 
become a treatment option for autoimmune rheumatic disease. However studies on 
the neutralisation of IFN-α (sifamumab, rontalizumab) or blockade of the IFNAR1 
receptor (anifrolumab) have had mixed results in phase II clinical trials[20]. In a 
phase IIb study, sifalimumab met its primary end point of a reduction in global 
disease activity score in patients with SLE. Efficacy was reported in the high IFN 
signature group but not the low IFN signature group, which may be a reflection of 
IFN expression or related to cohort size[339]. Surprisingly, rontalizumab in a post-
hoc analysis showed superior response in patients with a low baseline IFN 
signature[374]. This may be explained by the lower serological activity in the IFN low 
signature group, which suggests a milder disease cohort, or the higher trough 
concentrations of rontalizumab which may be cause for the difference[374]. 
Anifrolumab, an IFNAR1 monoclonal antibody antagonist, reduced global disease 
activity in a phase II trial in moderate-to-severe SLE[338]. The IFN high signature 
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group showed superior response which was clearly associated with increased 
anifrolumab concentrations[338]. Preliminary results from a recent phase III trial on 
anifrolumab failed to meet the primary end point of reduction in disease activity in 
patients with SLE, as measured by the SLE Responder Index 4 (SR14)[375]. 
Specific organ responses and subgroup analysis of the IFN high signature subgroup 
is yet to be published[375]. 
IFN Score A and IFN Score B are validated continuous 2-score systems for the 
measurement of IFN status[24]. The systems were developed using Factor Analysis 
of 31 ISGs as expressed within sorted PBMCs from SLE, RA and Healthy 
controls[24]. Score A represents a weighted composite expression score as derived 
from 12 co-clustering ISGs (ISG15, IFI44, IFI27, CXCL10, RSAD2, IFIT1, IFI44L, 
CCL8, XAF1, GBP1, IRF7, CEACAM1)[24]. Score B represents a weighted 
composite expression score from 14 co-clustering ISGs (LAMP3, IFIH1, PHF11, 
SERPING1, IFI16, BST2, SP100, NT5C3B, SOCS1, TRIM38, UNC93B1, UBE2L6, 
STAT1, TAP1)[24]. Score A and Score B differ between PBMC cell subsets, 
highlighting the importance of cell selection[24, 25]. There is a comparable 
distribution in range between SLE and healthy controls, but with marginal yet 
statistically higher values observable in SLE[24]. It is thought that the system may 
have greater discrimination in characterisation of IFN status over bimodal (i.e. 
high/low) assays[24]. Score A and Score B have been shown to correlate with lupus 
serology and features of disease activity (BILAG domains) in adjusted models[24]. 
In a small retrospective analysis Score A was significantly associated with lupus 
flares and Score B with severe lupus features (e.g. internal organ involvement)[352]. 
Score A and Score B have been shown to be predictive of progression to 
autoimmune connective tissue disease in an at risk cohort[25]. Memory B cell 
tetherin (tetherin) was shown to be predictive of disease severity and future activity 










Chapter 3 General methodology 
3.1 Introduction 
This chapter outlines the methodology that underpins the IFN assays and patient-
reported outcome measures described in this manuscript.  
3.2 IFN Score A and IFN Score B 
A two-score system of ISGs was briefly described in Chapter 2.3.8. IFN Score A and 
IFN Score B was calculated without knowledge of the participant’s clinical status.  
3.2.1 Gene probe selection and gene expression 
Ten genes were selected from each IFN-annotated module (M1.2, M3.4, M5.12) of a 
previous microarray study as reported by Chiche and colleagues (2014), with 
addition of other common IFN ISGs[25, 376]. This summated to a panel of 31 ISGs. 
The reference gene peptidyl prolyl isomerase A (PPIA) was selected due to non-
response to IFN-I.  
Using density gradient method (LymphoprepTM, Alere Technologies, Norway), 
peripheral blood mononuclear cells (PBMCs) were separated 
ethylenediaminetetraacetic acid (EDTA) anticoagulated blood. Total ribonucleic acid 
(RNA) was extracted from PBMCs and sorted cell subsets using the total ribonucleic 
acid purification kit (Norgen Biotek, Canada). Fluidigm® Reverse Transcription 
Master Mix buffer was mixed with random primers and oligo dT for priming to obtain 
the complementary DNA (cDNA) synthesis from total RNA acquired. TaqMan 
assays (Applied Biosystems, Invitrogen) were used to perform the quantitative real-
time reverse transcriptase-polymerase chain reaction (qRT-PCR) for the selected 31 
ISGs. The instruments used were the BioMark™ HD System with appropriate 
cycling protocols for the 96.96 chip. Data were normalised to the reference gene 
PPIA to calculate ∆Ct. 
3.2.2 Factor analysis 
Factor analysis (FA) was performed to reduce the 31 ISGs into a smaller number of 
factors[25]. Proceeding this, undetected ∆Ct values were singly imputed using the R 
package non-detects. The Kaiser-Meyer-Olkin measure was incorporated for 
verification of the sampling adequacy of the analysis. Principle factor extraction 
(without rotation) was used to determine the optimum number of factors, which was 
firstly calculated according to a parallel analysis (Monte Carlo simulation using 1000 
replications).This indicated the maximum number of factors however if a smaller 
number was required to explain >80% of the variance and resulted in lower levels of 
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cross loading (genes loaded by ≥2 factors at >0.4), the selection was then of a 
simpler structure. Following identification of the number of factors present, the final 
factor solution was determined from oblique (promax; kappa = 4) rotation.  
This study calculated the factor scores for each participant using median gene 
expression loaded at ≥0.4 by each factor provided that there was no greater cross 
cross-load than one factor. The strength of this approach is in its reflection of the 
variability of the data and the avoidance of compromise of the within-participant 
ordinal scaling of ∆Ct values.     
As described in the literature, 84% if the variance with limited cross-loading could be 
explained by two factors among the ISGs[24]. The ISGs that contributed to each 
factor are shown in the table (Table 14) and are distinguished by the names IFN 
Score A (12 co-clustered genes) and IFN Score B (14 co-clustered genes).   
Table 14 IFN Score A and IFN Score B 




Rotated Factor Loading 
Factor 1: 
IFN-I Score A 
Factor 2: 
IFN-I Score B 
ISG15 1.2 0.96*  
IFI44 1.2 0.80*  
IFI27 N/A 0.77*  
CXCL10 1.2 0.71*  
RSAD2 1.2 0.70*  
IFIT1 1.2 0.67*  
IFI44L 1.2 0.66*  
CCL8 3.4 0.58*  
XAF1 1.2 0.54*  
IFI6 N/A 0.51 0.45 
GBP1 3.4 0.46*  
IRF7 3.4 0.46*  
CEACAM1 3.4 0.45*  
HERC5 1.2 0.43 0.59 
EIF2AK2 3.4 0.42 0.64 
MX1 1.2 0.40 0.56 
LAMP3 1.2  0.40* 
IFIH1 3.4  0.45* 
PHF11 5.12  0.58* 
SERPING1 1.2  0.60* 
IFI16 5.12  0.64* 
BST2 5.12  0.74* 
SP100 5.12  0.74* 
NT5C3B 5.12  0.80* 
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SOCS1 3.4  0.84* 
TRIM38 5.12  0.87* 
UNC93B1 5.12  0.88* 
UBE2L6 3.4  0.89* 
STAT1 3.4  0.94* 
TAP1 5.12  0.98* 
CASP1 5.12 <0.40 <0.40 
Table 14. *Indicates genes included in the factor scores 
3.3 Memory B cell tetherin 
3.3.1 Introduction 
Memory B cell tetherin was briefly introduced in Chapter 2.3.8. It is a flow cytometric 
membrane bound protein (also known as bone marrow stromal cell antigen 2 / BST2 
/ CD317) responsive to interferon activity and measurable on the cell subset of 
choice, in the case of this study, memory B cells[373]. Memory B cell tetherin was 
calculated without knowledge of the participant’s clinical status. 
3.3.2 Sample preparation 
PBMCs were separated using density gradient method (Lymphoprep®, Alere 
Technologies, Norway) from EDTA-anticoagulated peripheral blood. Isolated cells 
were twice washed by Dulbecco’s Phosphate-Buffered Saline (DPBS) and were 
labelled with a panel of monoclonal antibodies for immunotyping or FACS cell 
sorting.  
3.3.3 Antibody clones 
The antibody clones used in this study were: CD19 (clone HIB19). The following 
antibody clones were used in this study; CD19 (clone HIB19); CD69 (clone FN50); 
CD56 (clone B159), CD3 (clone SK7), CD4 (clone RPA-T4); CD8 (clone SK1); 
CD27(clone M-T271), all from BD Biosciences (Oxford, UK); CD14 clone TÜK4); 
CD16 (clone Clone VEP13), CD38 (clone DX9); CD64 (clone 10.1.1), CD169-
Siglec-1 (clone 7-239), all from Miltenyi Biotec (Bisley, UK) and 
BST2/tetherin/CD317 (clone 26F8) from eBiosciences (Hatfield, UK). 
3.3.4 Flow cytometry and cell sorting 
A multiflow analysis was applied to detect and quantify the tetherin on PBMCs. A 
gating strategy was used to define and sort cells into T-cells, NK-cells, monocytes 
as well as B cell subsets: naïve, memory and plasmablasts using a BD Influx™ cell 
sorter (Figure 4). For each population, mean fluorescence intensity (MFI) of tetherin 
BD was determined using FACSCanto flow cytometer and BD FACSDiva software. 
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The memory B cell tetherin MFI of CD19+CD27+CD38- lymphocytes was selected for 
this study. 
Figure 4 Flow cytometry for memory B cell tetherin 
 
Figure 4. Memory B cell tetherin flow cyotmetry 
3.4 Patient reported outcome measures 
3.4.1 Introduction 
Many patient-reported outcome measures (PROMs) have been validated for use in 
adults with CTD[377]. The instruments are usually in the form of a questionnaire and 
can be used to assist health professionals and researchers to gain insight into a 
patient’s perspective of health. PROMs may be generalised or have a specific focus 
on matters relating to the patient’s experience. In light of the heterogeneity of CTD, 
this research program included a variety of PROMs for the purpose of gaining an in-
depth understanding of the patient’s perspective. Indices were administered to 
participants for completion at the time of the study visit and were analysed in 
accordance with published scoring rules, as described as follows.   
3.4.2 Visual analogue scales (VAS) 
Visual analogue scales (VAS) for pain, morning joint stiffness, arthritis, fatigue, and 
global health was administered to measure symptom severity and general health. 
Each VAS was a single item that measured response on a 100 mm continuous 
horizontal scale. Endpoints were no symptoms or best health (0) and worst 
symptom or worst health (100). Participants were directed to mark on the scale at a 
site that corresponded with the severity of their symptoms in the past month. 
Missing data was excluded in analyses.  
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3.4.3 RAND® 36-Item Health Survey version 1.0 (SF-36) 
The RAND® 36-Item Health Survey version 1.0 (SF-36) was administered to 
measure general health and quality of life. The instrument reports on eight health 
concepts: physical functioning, bodily pain, role limitations due to physical health 
problems, role limitations due to personal or emotional problems, emotional well-
being, social functioning, energy/fatigue, and general health perceptions. The 
responses were scored in accordance with RAND® Instrument scoring rules[378]. 
Missing data was omitted in analyses. 
3.4.4 5-level EQ-5D version (EQ-5D-5L)  
The 5-level EQ-5D version (EQ-5D-5L) consists of the EQ-5D descriptive system 
and the EQ visual analogue scale (EQ-VAS)[379]. The EQ-5D-5L is a standardised 
measure of health status that relates to the respondent’s situation at the time of 
completion. The descriptive system is comprised of five dimensions: mobility, self-
care, usual activities, pain/discomfort and anxiety/depression. Each dimension has a 
response option of either no problems, slight problems, moderate problems, severe 
problems or extreme problems. The EQ-VAS records the respondent’s self-rated 
health on a 20cm, 100 point vertical VAS, where the endpoints were labelled ‘The 
worst health you can imagine’ (or 0) and ‘The best health you can imagine’ (or 100). 
Respondents mark an X on the scale to indicate how their health is today, and write 
the number they marked on the scale within an adjacent box. Responses for the 
EQ-5D descriptive system were coded as either 0 for no problems, or 1 for slight, 
moderate, severe or extreme problems. The EQ-VAS was scored according to the 
number in the box, or if missing, scored according to the site marked with X on the 
scale. Missing values were excluded from analyses.      
3.4.5 Work productivity and Activity Impairment Questionnaire: Specific 
Health Problem version 2.0 (WPAI:SHP) 
The Work productivity and Activity Impairment Questionnaire: Specific Health 
Problem version 2.0 (WPAI:SHP) is a measure of work and activity impairment due 
to a target health problem[380]. The WPAI:SHP yields four types of scores: 
absenteeism (work time missed), presenteeism (impairment at work or reduced on-
the-job effectiveness), work productivity loss (overall work impairment or 
absenteeism plus presenteeism) and activity impairment. WPAI:SHP outcomes are 
expressed as impairment percentages, with higher numbers indicating greater 
impairment and less productivity. Missing items were excluded from analyses.      
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3.4.6 ICEpop CAPability measure for Adults (ICECAP-A) 
The ICEpop CAPability measure for Adults (ICECAP-A) is a generic measure of 
capability for well-being in adults[381]. ICECAP-A conceptualises well-being as the 
capability of the individual to achieve valuable functioning in five attributes: 
attachment, stability, achievement, enjoyment and autonomy. Previous work on the 
ICECAP-A suggests that the instrument can comprehensively capture quality of 
life[381]. Respondents indicate their level of capability for an attribute on a four-
tiered Likert scale. ICECAP-A Instrument scoring guidance was used to code and 
produce respondent tariff values[382]. Only complete case data were analysed.   
3.4.7 Functional Assessment of Chronic Illness Therapy - Fatigue Scale 
(FACIT-Fatigue) 
The Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-
Fatigue) version 4 is a 13-item questionnaire that assesses quality of life concerns 
related to fatigue[383]. It measures an individual’s level of fatigue on a four point 
Likert scale during their usual daily activities over the past week. Responses were 
scored in accordance with the FACIT-Fatigue Subscale Scoring Guidelines (Version 
4)[384]. Missing items were handled using a proration method where the calculation 














Chapter 4 In SLE patients validated interferon assays predict flares and 
glucocorticoid requirements 
4.1 Introduction 
Damage accumulates and long-term mortality and quality of life remains impaired 
despite current therapies in lupus[55]. Disease activity and glucocorticoid use are 
recognised predictors of poorer long-term outcomes[55]. Treat-to-target strategies 
are known to improve long term outcomes in other rheumatic diseases[55]. In light 
of this, the 2010 EULAR treat-to-target guidelines were created for the management 
of SLE[55]. The guidelines recommended minimisation of glucocorticoids, the 
achievement of lowest disease activity, and the goal-directed use of validated 
activity indices and/or organ-specific biomarkers as the benchmarks of lupus best 
care[55]. Achieving these aims is a challenge, glucocorticoid minimisation in 
particular, as there are few reliable means to predict future disease activity and 
therefore guide withdrawal decisions. There is therefore an unmet need for 
biomarkers that can predict future therapy. 
Potential biomarkers in lupus are numerous including cytokines, chemokines, 
growth factors and acute phase reactants[19, 222, 385]. However, there are 
inconsistent reports on the performance of many of these biomarkers to discriminate 
activity, and most have been studied in small cohorts or cross-sectional 
observational studies[18]. Demonstrating association between a potential biomarker 
and diagnosis or disease activity suggests that it may contain important information 
about a disease, but the more critical aspect of biomarker validation is the ability of 
the biomarker to predict clinical outcomes of value[18]. Data on this are more 
limited, which prevents the incorporation of many biomarkers into clinical practice 
[20, 25]. 
IFN-I plays a fundamental role in the pathogenesis of SLE and is known to be 
associated with disease activity[20]. IFN-I has numerous pleiotropic effects but 
remarkably IFN-I stimulates B cell activation which is a pre-requisite for plasmablast 
and plasma cell differentiation, a key pathway of disease pathogenesis in SLE[20]. 
IFN-I protein is difficult to detect in the blood or serum directly[19, 343, 376]. IFN-I 
status is therefore more commonly determined using the expression of IFN-
stimulated genes (ISGs). There are over 100 genes induced by type I IFN pathway 
activation and the choice of which ISGs to include and how to summarise results 
affects the validity of scores[343, 368]. The metric properties of ISG expression has 
been described to be improved by (i) analysing ISGs as more than one score, and 
(ii) describing interferon activity as a continuous score rather than a simple high / 
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low “signature”[24]. A two-score system IFN Score A and IFN Score B was recently 
shown to predict future development of SLE[25]. 
An alternative approach to IFN status determination is the measure of tetherin, a 
flow cytometric surface marker[373]. Tetherin is a IFN-stimulated cell surface protein 
expressed on all nucleated cells[373]. It has been validated on memory B cells as a 
biomarker of disease activity in SLE[24].  
The purpose of the present study was to evaluate these IFN biomarkers to examine 
the therapeutic goals of predicting disease activity and glucocorticoid requirement. 
We also sought to compare these continuous scores with the more commonly used 
categorical high / low measure of IFN status used in other studies[339, 347, 374, 
386-390]. If appropriately validated, this could allow the clinical application of these 
biomarkers to guide decisions regarding management of immunosuppression. 
4.1.1 Hypothesis 
i. Risk of future flares and oral glucocorticoid requirements in SLE can be 
predicted using IFN Score A, IFN Score B and memory B cell tetherin 
4.1.2 Objectives 
i. To evaluate disease activity and glucocorticoid requirements relative to IFN 
biomarker sampling in a cohort of SLE patients 
4.2 Methods 
4.2.1.1 Ethical approval and methods 
The Leeds Human Research Ethics Committee (approval RR10/9608) granted 
ethical approval for the study (Chapter 9). This study was a retrospective study that 
used the Connective Tissue Disease and Vasculitis Longitudinal Cohort (CONVAS) 
database and was conducted at the Leeds Teaching Hospitals NHS Trust. 
Consecutive patients with SLE meeting SLICC-12 classification criteria who 
submitted IFN biomarker samples (IFN Score A, IFN Score B and/or memory B cell 
tetherin) were identified and selected into this cohort study. A total of 166 patients 
were selected. 
Medical records were then used to determine outcome measures. British Isles 
Lupus Activity Group 2004 index (BILAG-2004) was used to determine disease 
activity. Average monthly prednisolone dose was calculated for the three months 
before and after biomarker submission. Glucocorticoids were adjusted for equivalent 
prednisolone dose (i.e. hydrocortisone was prescribed for one patient which was 
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recalculated into the equivalent prednisolone dose). The clinical assessors were 
blinded to IFN assay results. 
Case data was divided into two subgroups to address each objective (Figure 5). 
Group 1: patients with no BILAG-2004 A or B activity in the six months prior to 
biomarker submission. Group 2: patients with any level of disease activity who had 
available records for prednisolone dosing for the three months before and after 
biomarker submission.  
Figure 5 Schema of case selection. 
 
4.2.1.2 Clinical endpoints 
The objective of Group 1 was to examine the relationship between biomarker 
expression and the clinical outcome of flare or no flare. The clinical endpoint in 
Group 1 was new onset of BILAG-2004 A or B activity in the six month period after 
biomarker submission. The objective of Group 2 was to examine the relationship 
between biomarker expression and pattern of prednisolone requirement. The clinical 
endpoint in Group 2 was change in prednisolone exposure relative to the time of 
biomarker submission. Change in prednisolone exposure was determined by 
comparing the total mean monthly prednisolone equivalent dose between the 
periods pre- and post-biomarker submission. Categories of prednisolone change 
patterns were: dose increased; dose decreased; no change; or no prednisolone 
prescribed before or after biomarker sampling. 
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4.2.1.3 Interferon assays 
The development and validation of IFN assays are described in detail in Chapter 3 
[24, 373]. IFN Score A and IFN Score B are a 2-score system derived from factor 
analysis of 31 ISGs selected from three IFN annotated modules as measured by 
TaqMan[25]. Briefly, RNA was extracted from PBMCs and a custom TaqMan array 
was used to measure the expression of 31 ISGs normalised to PP1A. These were 
then used to calculate Score A and Score B. For memory B cell tetherin, PBMCs 
were analysed fresh with conventional surface staining. MFI of CD317 was 
measured on CD19+CD27+CD38- lymphocytes. 
IFN Scores were initially calculated as an untransformed delta cycle threshold (dCT) 
normalised to the reference gene PP1A. Untransformed scores lead numerically 
higher scores for a patient with lower ISG expression. For clarity of presentation we 
therefore presented the reflected dCT (dCT x -1) in graphs and tables. 
4.2.2 Statistical analyses 
Two analyses were performed to examine the clinical associations of the three IFN 
assays. For Group 1, the onset of new disease activity (defined as new BILAG A or 
B activity) in patients in sustained low disease activity before biomarker submission 
(no BILAG-2004 A or B in the six months prior to IFN biomarker sampling was used 
as the definition of sustained low disease activity). For Group 2, the pattern of 
prednisolone change relative to the time of biomarker submission. Since memory B 
cell tetherin is measured on B cells we excluded patients who were B cell depleted 
due to rituximab exposure in the 6 months prior to biomarker submission. 
Independent samples t-test was used to compare IFN biomarkers between groups. 
Prediction of flare including age, gender, pre- and post-sampling prednisolone dose 
was performed using multivariate logistic regression. 
4.2.3 Results 
4.2.3.1 Overall clinical outcomes 
166 patients meeting SLICC 2012 criteria for SLE were identified from the database. 
The study schema is shown in Figure 5. In Group 1, 99 patients were in sustained 
low disease activity prior to biomarker sampling and had complete data on flares 
and interferon status. New BILAG A or B activity occurred within 6 months in 11/99 
patients (11.1%). In group 2, 144 patients had complete data on glucocorticoid 
usage and IFN-I status. Mean monthly prednisolone doses were increased in 12 
(7.2%), decreased in 13 (7.8%), no change in 34 (20.5%), and were not prescribed 
in 85 (51.2%). 
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4.2.3.2 Baseline characteristics 
Baseline characteristics for the patient population and each group are shown in 
Table 15. A notable characteristic is that prednisolone exposure was lower in Group 
1 compared to Group 2 however this could be expected for a group of patients in 
low disease activity. Numerically higher rituximab use was found in Group 2, but 
there was no difference in internal organ involvement or cyclophosphamide 
exposure. Patients in Group 1 appeared to have well-controlled disease at the time 
of biomarker sampling, but historically had not always had mild SLE. 
Table 15 Baseline characteristics of the 166 SLE patients 
Characteristic 
Population  
N = 166 
Group 1 
N = 99 
Group 2 
N = 144 
Median Age (Range), Years 46 (18, 76) 42 (18, 74) 45 (18, 74) 
F : M 156 : 10 92 : 7 137 : 7 
Met SLICC 2012 criteria 100% 100% 100% 
Internal organ involvement 59.4%  55.6% 58.3% 
     No internal organ 
involvement 
40.6% 44.4% 41.7% 
     2 or more organs 18.7% 16.1% 18.8% 
Cyclophosphamide (ever) 28.3% 27.3% 27.8% 
Rituximab exposure (ever) 48.8% 39.4% 48.6% 
On prednisolone (pre-
biomarker) 
     Median dose (range) 
54/144 (37.5%) 
5mg (1, 22.5) 
29/99 (29.2%) 
1.8mg (1, 22.5)  
54/144 (37.5%) 
8.1mg (1, 22.5) 
On prednisolone (post-
biomarker) 
     Median dose (range) 
58/144 (40.3%) 
5.6mg (1, 25) 
31/99 (31.3%) 
1.62mg (1, 15) 
57/144 (40%) 
7.9mg (1, 25) 
Captured flare types  
     Arthritis 
     Skin 
     Arthritis + skin 
     Haematological 















4.2.3.3 Overall interferon score status  
The overall IFN Score A mean expression (95% CI) in delta CT was 3.57 (3.23, 
3.91) for the study population. Since many publications have reported a bimodality 
to IFN Score distribution, we re-classified the continuous IFN Score A into the two 
groups: high or low; as described in a previous paper from our group [24, 347, 365]. 
Briefly, the mean interferon score of samples from patients with SLE, RA, UCTD and 
healthy controls (n = 328) plus two standard deviations (SD) above the mean was 
calculated. Plus two SD was chosen as a conservative approach to the analysis of 
the data. Therefore, a value of ≥2.32 was designated as IFN Score A high[391]. For 
IFN Score B, overall mean expression (95% CI) in delta CT was 3.18 (3.01, 3.34). 
100% of SLE patients had high IFN Score B expression. Mean MFI for memory B 
cell tetherin (95% CI) was 1708 (1596, 1820). 
In the following analyses, the clinical outcomes and the level of expression of each 
IFN biomarker has been compared for the whole group and within the IFN Score A 
high expression subgroup. 
4.2.3.4 Prediction of flares (Group 1) 
New BILAG A/B activity in the 6 months after biomarker submission (Group 1) was 
associated with significantly higher expression of IFN Score A, IFN Score B and 
memory B cell tetherin MFI (Figure 6). The mean difference (95% CI) for IFN Score 
A was 2.16 (0.369, 3.954, p=0.02), for IFN Score B was 0.694 (0.025, 1.364, 
p=0.04) and for memory B cell tetherin MFI the mean difference 1045 (1718, 371, 
p=0.003). Using the bimodal classification, all flares occurred in patients with high 
IFN Score A status. 
Figure 6 Mean IFN Score A, IFN Score B and memory B cell tetherin levels 
relative to new disease activity in the post-sampling period 
 
Figure 6. Mean IFN Score A, IFN Score B and memory B cell tetherin levels in 
lupus patients in low disease activity relative to new disease activity in the six month 
post-sampling period (left-to-right): IFN Score A, IFN Score B and Memory B cell 
tetherin levels. Error bars in figure legends represent 95% Confidence interval. 
Significant associations with BILAG A or B flares remained for IFN Score A (n=73, 
OR=1.57/unit (95% CI 1.02, 2.40) p=0.040), and memory B cell tetherin MFI (n=46, 
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OR=6.46/1000units (95% CI 1.25, 33.3) p=0.026) after adjustment for age and post-
sampling steroid dose in logistic regression. IFN Score B did not produce 
significance in logistic regression, but showed a positive trend: IFN-I Score B (n=73, 
OR=1.86/unit (95% CI 0.81, 4.30) p=0.144). 
Despite small study numbers, Receiver Operator Curve analysis of memory B cell 
tetherin was undertaken as a single biomarker for flare prediction (Figure 7) to 
estimate whether the clinical utility of the test. A threshold of tetherin=2403 units MFI 
produced 80% sensitivity and 85.4% specificity for flare. Application of this threshold 
finds that 10.3% of patients would be expected to flare in a Tetherin-low group, and 
36.4% of patients would flare in a Tetherin-high group; a group that included 16% of 
all included patients. 
Figure 7 Receiver operator curve for prediction of flare and tetherin 
 
Figure 7. Receiver operator curve for prediction of flare (new BILAG A or B) using 
memory B cell tetherin. A threshold of tetherin=2403 units MFI gave a sensitivity of 
80% and specificity of 85.4% for flare. 
4.2.3.5 Prediction of glucocorticoid use (Group 2) 
Analysis of the four steroid pattern groups confirmed clinically meaningful changes 
in prednisolone dose change within Group 2 (Figure 8-A). The mean steroid dose 
remained at 5mg per day (SD 4.73) over the 3 months before and after biomarker 
sampling in the “no change” subgroup. For the “increased” subgroup, the mean 
steroid dose increased from 5mg per day (SD 6.10) to 10mg per day (SD 5.57). For 
the “decreased” subgroup, the mean steroid dose reduced from 10mg per day (SD 
5.64) to 7.5mg per day (SD 4.57). 
Overall trends in IFN status within these subgroups are provided in Figure 8 B-D. 
These demonstrate a significant association between high IFN biomarker status and 
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future prednisolone need. Future requirement for the same (p=0.007) or an 
increased (p=0.002) dose of prednisolone was associated with significantly higher 
IFN Score A expression compared to a decreased prednisolone dose. IFN Score B 
(p=0.022 and p=0.026 respectively) demonstrated a similar pattern. Compared to 
individuals not requiring prednisolone, increased prednisolone need was predicted 
by significantly higher IFN Score A and Score B (p=0.004 and p=0.047 respectively). 
The overall pattern was similar for memory B cell tetherin MFI levels (despite patient 
numbers being lower). Greater memory B cell tetherin MFI correlated with exposure 
to the same (p=0.032) or an increased (p=0.039) dose of prednisolone compared to 
a decreased dose of prednisolone. Statistical data in full are shown in Table 16. 
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Figure 8 Mean IFN Score A, IFN Score B and memory B cell tetherin levels 
relative to prednisolone dose change in the biomarker peri-sampling period 
 
Figure 8. From left to right, above to below (A) Prednisolone dose change pattern 
relative to mean prednisolone dose within the cohort, pre- and post-biomarker 
sampling; (B) mean IFN Score A level relative to prednisolone dose change pattern; 
(C) mean IFN Score B level related to prednisolone dose change pattern; (D) mean 
IFN memory B cell tetherin relative to prednisolone dose change pattern; (E) IFN 
High Score A group only: mean IFN Score A (high group) relative to prednisolone 
dose change pattern. X axis denotes subgroups of prednisolone change. Patient 
numbers in brackets. Error bars in figure legends represent 95% Confidence 
interval.     
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Table 16 Comparison between prednisolone dose change categories 














No prednisolone Increased† 2.13 0.004 0.70 3.55 
Decreased‡ 0.75 0.261 -2.07 0.57 
No change‡ 1.27 0.010 0.31 2.23 
Increased Decreased‡ 2.88 0.002 4.67 1.09 
No change‡ 0.86 0.280 -2.41 0.69 
Decreased No prednisolone† 0.75 0.260 -0.57 2.07 







No prednisolone Increased† 0.69 0.047 0.01 1.37 
Decreased‡ 0.28 0.372 -0.92 0.35 
No change† 0.53 0.024 0.07 0.99 
Increased Decreased‡ 0.98 0.026 1.83 0.12 
No change‡ 0.16 0.672 -0.90 0.58 
Decreased No prednisolone† 0.29 0.372 -0.35 0.92 




















No prednisolone Increased† 333 0.287 -950 283 
Decreased‡ 547 0.068 -41 1136 
No change† 325 0.096 -710 58 
Increased Decreased‡ 880 0.032 79 1681 
No change‡ 8 0.982 -657 673 
Decreased No prednisolone† 547 0.068 -1136 41 
No change† 872 0.008 1512 233 
Table 16. † = higher biomarker group; ‡ = lower biomarker group 
4.2.3.6 Continuous vs Categorical IFN Status 
The question of whether a continuous IFN score could provide clinically meaningful 
information over and above bimodal high/low categorical IFN scores (as reported in 
other studies) was tested by repeat analysis using the cases of high IFN Score A 
status only[347, 369]. This analysis found that more extreme elevations of IFN 
Score A expression were associated with higher predicted prednisolone needs 
compared to the rest of the IFN Score A-high group. Level of IFN Score A 
significantly correlated with remaining on the same dose of glucocorticoid (p=0.041) 
and increasing the dose of glucocorticoid (p=0.017) compared with a future 
prednisolone dose decrease. This indicates that continuous IFN score systems may 
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have an advantage over bimodal IFN score systems in terms of addressing the 
question of prediction of future glucocorticoid need. 
4.2.4 Discussion 
Quantification of IFN-I activity in SLE using IFN Score A, IFN Score B and memory 
B cell tetherin MFI is demonstrated in this study to predict outcomes previously 
recommended by an international guidelines as targets for the management of SLE. 
IFN Score A, IFN Score B and memory B cell tetherin may therefore assist with 
treatment pathways.  
The maintenance of low disease activity is strongly evidenced: in longitudinal 
studies disease activity was associated with eventual damage and mortality, while 
attaining low disease activity or remission predicted better long-term health 
status[392-395]. In patients who achieve low disease activity, the future flare rate 
has been reported as 64-75% in cohorts, with 17-38% of these being severe. 
Sustained remission is observable in 10-40% of patients. Identifying the individuals 
at highest risk of flare is an opportunity for prevention through pre-emptive addition 
of non-glucocorticoid immunosuppression. Although our study included a relatively 
small number of flares, we have estimated the potential utility of using IFN 
biomarkers for this purpose. In our data, a level of memory B cell tetherin, the best 
biomarker, over a critical threshold was associated with a tripling of flare rate, from 
10% to 36%. In vivo, if high tetherin were used to trigger escalation of therapy in the 
16% of all low disease activity patients approximately 40% of all flares could 
potentially be prevented.  
Apart from disease activity, another major predictor of negative long term outcomes 
is the use of glucocorticoids, which generates an additional dilemma in patients on 
long term glucocorticoids when the risk of flare on tapering is unpredictable[396]. If 
activity was allowed to occur on tapering of prednisolone, as well as potential 
damage accumulation, the ultimate result may be a higher total cumulative 
glucocorticoid dose than if withdrawal was never attempted. In our cohort IFN 
biomarkers were able to differentiate changes in glucocorticoid requirement of a 
mean increase of 5mg, mean decrease of 2.5mg and clusters of patients whose 
ultimate mean prednisolone dose was more than 10mg. These levels are clinically 
significant in terms of long term glucocorticoid toxicity. The hazard ratio for damage 
is 1.05 per 1mg of prednisolone, and is 1.50 for use of doses over 6-12mg[397, 
398]. Our results therefore suggest that IFN biomarkers could identify patients in 
whom glucocorticoid doses could be safely reduced by a margin that practically 
alters long term outcome and without increasing the risk of activity. 
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The challenges in measuring IFN status is well recognised, which is reason for the  
vast array of potential IFN biomarkers published. Importantly, many of these 
biomarkers have not been able to establish the same correlations that were found in 
this study. For instance, Petri et. al. researched the predictive performance of an 
ISG IFN status assay for prediction of flare and found no correlation[369]. The 
difference from these results is likely because the results from other studies used 
semi-quantitative micro-array findings limited to 3 ISGs, while our gene expression 
results were calculated using 2 fully-quantitative scores that had already been 
validated against a range of other in-vitro and clinical outcomes. Head-to-head 
comparisons of the clinical utility of different biomarkers are few. A strength of this 
study is that 3 biomarkers were analysed in the same population for the same 
endpoints. 
IFN status using two scores has been previously shown to strengthen clinical 
associations, and each score has been correlated with different clinical 
characteristics. While patients with SLE have high levels of both IFN Score A and 
IFN Score B, patients with RA have been shown to have high levels of IFN Score B 
only[24]. IFN-Score-B has previously only been shown to be a better predictor for 
the progression to SLE in an at risk population than IFN-Score-A. For the particular 
endpoints in this study the three assays demonstrated broadly similar 
characteristics, but with some difference in the strength of correlations. 
The differences in expression between IFN Score A and IFN Score B from a 
biological point of view is not entirely clear. These scores were derived from 
previously described modules of IFN-stimulated genes; IFN Score A mostly from 
module 1.2 and 3.4 and IFN Score B mostly from module 3.4 and 5.12[376]. These 
modules were previously thought to represent response to Type I and Type II 
interferons. However, changes in gene expression may also reflect other 
inflammatory cytokines or differences in the cellular composition of the sample. In 
this respect it is remarkable that tetherin measured specifically on B cells was 
somewhat more predictive than the other assays. 
Another possible clinical application for a predictive IFN assay has been patient 
selection for IFN-targeting drugs. In the clinical trials of anifrolumab and 
sifalimumab, IFN-high patients showed a better clinical response in the active arms 
compared to placebo[20]. However alternatively, this was due to a lower response 
rate in the IFN-high patients randomised to placebo. Our findings on flares and 
prednisolone use would match the inability to meet a composite endpoint such as 
SRI-4 with prednisolone taper. Our results therefore suggest that IFN status could 
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stratify and dictate the placebo response rate for a clinical trial of any investigational 
therapy compared to placebo, not just IFN-blocking drugs. 
4.2.5 Conclusion 
In conclusion, the value of IFN biomarkers has been demonstrated for a specific 
clinical decision including a head to head comparison of different IFN biomarker 
subtypes and analyses. These results warrant validation studies to confirm that 
addition of immunosuppressive therapy, or prednisolone withdrawal based on 
biomarker results are effective in a clinical study. The Defining Interferon-mediated 
Connective Tissue Disease (DEFINITION) study is a prospective longitudinal cohort 
study that is currently investigating this idea. 
4.2.6 Key messages 
 Validated interferon assays predict activity and glucocorticoid use in lupus and 
may therefore aid achievement of low disease activity 
 IFN stimulated gene expression should be analysed as a continuous variable not 
a simple high “signature” 
 Further validation study of IFN Score A and IFN Score B is necessary to explore 





















Chapter 5  The use of IFN assays in distinguishing patients who met CTD 
classification criteria from a cohort of patients labelled as UCTD 
5.1.1 Introduction 
Undifferentiated connective tissue diseases (UCTD) is a term used to describe 
patients that who exhibit signs, symptoms and serological abnormalities suggestive 
of an underlying autoimmune disorder, but who do not fulfil any classification criteria 
for definitive CTDs such as SLE, pSS, SSc, IMs and others[116]. Patients with 
UCTD have detectable ANAs and sometimes positive autoantigen specificities. 
Arthralgia, arthritis, rash, alopecia, Raynaud’s phenomenon, mucosal ulcers, 
photosensitivity, sicca and low grade fever are common symptoms in UCTD[115]. 
Although the term "undifferentiated" sounds uncertain or vague, the condition can 
substantially affects patients’ quality of life [399]. Moreover, the prognosis of UCTD 
could be disease stability, regression to remission, or progression to a classifiable 
form of CTD[112, 116]. Therefore, there is an unmet need for prognostic biomarkers 
to stratify those likely to progress to the classification criteria of established 
CTD[116-118, 126, 400]. 
As described in Chapter 2.3.8, variants in IFN-I pathway are prominent in the 
genetic susceptibility to CTDs and therefore are a focus for investigation[401-403]. 
Our group, previously published that IFN Score B was an independent predictor of 
progression from at risk individual (i.e. defined as ANA positive; ≤1 clinical SLE 
criterion; symptom duration <12 months and treatment-naïve) to meeting criteria for 
CTD[404]. However, the role of IFN in UCTD cohort is less well documented and is 
currently unclear. In one cross-sectional study, of 28 patients recruited, 50% of the 
patients with UCTD had elevated IFN signature versus healthy controls, as 
measured by IFN-5 score i.e. summation of the expression levels of five IFN-
stimulated genes ([ISGs] - LY6E, OAS1, IFIT1, ISG15 and MX1), which were 
normalised to GAPDH gene. However, its significance has not been reported.  
Another important issue is related to the labelling of patients as UCTD. To date, the 
UCTD classification criteria are only provisional[114] and may be considered 
outdated in light of several recently published classification criteria for definitive 
CTDs[71, 80, 405, 406]. Moreover, these criteria can be difficult to use and may 
contain criterion considered subjective (e.g. alopecia, photosensitivity, mucosal 
ulceration and myalgia). Criteria need not be present all at the same time, further 
complicating accurate classification. Consequently, some patients who are labelled 
as UCTD could indeed meet the classification of definitive CTD, should these criteria 
78 
 
have been rigorously assessed. Biomarkers to support the differentiation between 
classifiable CTD and UCTD may help identify the former group, who may benefit 
from close monitoring and stronger immunosuppression based on patterns seen 
within peers.  
5.1.2 Hypothesis 
i. The use of IFN Score A and IFN Score B will support identification of 
patients with classifiable CTD from a cohort of patients labelled as UCTD. 
5.1.3 Objectives 
i. To evaluate the use of IFN assays in distinguishing patients with classifiable 
CTD immunologically from a cohort of patients labelled as UCTD.  
5.2 Methods 
5.2.1 Design and Patients 
A cross-sectional study of consecutive patients with UCTD was conducted at a 
single centre in Leeds between July 2017 till March 2019. Inclusion criteria were (i) 
ANA positive; (ii) signs and symptoms suggestive of CTD but not fulfilling 
classification criteria for an established CTD[38, 71, 80, 405] or RA [407]; disease 
duration of at least 12 months and iv) UCTD diagnosis made by Consultant 
Rheumatologists. 
5.2.2 Ethical approval  
All individuals provided informed written consent and this research was undertaken 
in compliance with the Declaration of Helsinki (Chapter 9). The patients’ blood 
samples used for this study were collected under ethical approval, REC approval 
17/YH/0166, National Research Ethics Committee Yorkshire and the Humber – 
South Yorkshire. All experiments were performed in accordance with the relevant 
guidelines and regulations. The University of Leeds was contracted with 
administrative sponsorship.  
5.2.3 Assessment and Clinical data collection 
Patients with a Consultant diagnosis of UCTD were recruited from the National 
Health Service (NHS) Leeds Connective Tissue Disease Clinic. The research 
assessment took place within 3 months from the last patient visit to this NHS clinic. 
At this research visit, age, gender, ethnicity, history of first or second degree 
relative(s) with rheumatic and musculoskeletal diseases (RMDs), smoking history, 
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presence of fibromyalgia, treatment including DMARDs, corticosteroids, disease 
features and number of classification criteria met for CTD based on previous clinic 
letters and medical notes were recorded. Patients were then schematically 
assessed for classification criteria of the four most common CTDs: SLE[38], 
pSS[71], SSc[80] and IMs[405]. Any discrepancy in the assessment of UCTD 
classification between both physicians was recorded. 
5.2.4 Laboratory assessment 
ANA was tested using a panel of nuclear autoantibodies that included anti-dsDNA 
and extractable nuclear antigens (including Ro52, Ro60, La, Sm, Chromatin, RNP, 
Ribosomal P, Jo-1, Centromere and Scl-70) using the Bioplex 2200 Immunoassay. 
Full blood count, liver function and electrolytes were processed at a single 
accredited diagnostic laboratory. Complement levels (C3 and C4) were measured 
by nephelometry. Samples for IFN biomarkers were collected and processed as per 
Chapter 3.2. IFN Score A and IFN Score B were calculated without knowledge of 
the participants’ clinical status. 
5.2.5 Statistical analyses 
Descriptive statistics were summarised using mean with standard deviation or 
median with interquartile range for continuous variables (where appropriate) and 
proportion for categorical variables. The independent samples T-test was used to 
analyse the difference in the IFN Scores between patients with classifiable CTDs 
and those who remained undifferentiated according to the investigator’s 
assessment. 
5.3 Results 
5.3.1 Patient Characteristics 
43 patients with a Consultant diagnosis of UCTD were enrolled into the study. Of 
these, 36 (84%) were females, mean (SD) age was 49.4 (12.4) years, median 
(range) disease duration was 4 (1-18) years, 7 (16%) had major internal organ 
involvement and 28 (65%) were on concomitant DMARDs (including anti-malarials). 






Table 17 Baseline characteristics of the 43 patients with UCTD 
Characteristics Values 
Age, mean (SD) years 49.4 (12.4) 
Female patients, N (%) 36 (83.7) 
Ethnicity, N (%) 
White  30 (71.4) 
Black 4 (9.5) 
South Asian 6 (2.3) 
Positive ANA, N (%) 43 (100) 
Autoantibody specificities 
Anti-dsDNA 9 (20.9) 
Anti-Ro (52 or 60) 12 (27.9) 
Anti-La 4 (9.3) 
Anti-Smith 1 (2.3) 
Anti-RNP 4 (9.3) 
Anti-Scl-70 2 (4.7) 
Anti-Jo1 1 (2.3) 
Anti-Centromere 1 (2.3) 
Anti-Ribosomal P 1 (2.3) 
Family history of autoimmune disease, N (%) 11 (25.6) 
Current smoker, N (%) 7 (17.1) 
Fibromyalgia, N (%) 5 (11.6) 
Disease duration, median (range) years 4 (1-18) 
No of clinical criteria for CTD, N (%) 
1 1 (2.3) 
2 15 (34.9) 
3 13 (30.2) 
4 8 (18.6) 
5 4 (9.3) 
≥ 5 2 (4.7) 
Internal organ involvement, N (%) 7 (16.2) 
ILD 2 
Myositis 2 
Peripheral neuropathy 3 
Concomitant DMARDs, N (%) 28 (65.1) 
Anti-malarials 18 (41.9) 
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Methotrexate 10 (23.3) 
Mycophenolate mofetil 1 (2.3) 
Azathioprine 3 (7.0) 
Sulfasalazine 1 (2.3) 
Concomitant glucocorticoids, N (%) 2 (4.7) 
Table 17. Characteristics.  
5.3.2 Clinical criteria of UCTD as assessed between Consultant diagnosis 
and the research investigator 
The median (range) duration of time when patients with UCTD were reviewed 
between NHS and research clinics was 4 (1-10) weeks. Following a schematic 
review of patients’ signs and symptoms against classification criteria for these four 
CTDs i.e. SLE, pSS, SSc and IMs at the research clinic, 9/43 (21%) patients met 
classification criteria for an established CTD. Of these, 6 patients were re-classified 
as SLE,  2 were definite or probable IMs and 1 was SSc. The differences in clinical 
criteria scored between a Consultant diagnosis and the schematic review by the 
research investigator are presented in Table 18. 
Table 18 Clinical criteria of UCTD as assessed between Consultant diagnosis 
and the research investigator 





of UCTD by 
investigator (n=43) 
Alopecia, N (%) 2 (22.2) 3 (33.3) 
Raynaud’s phenomenon, N (%) 4 (44.4) 4 (44.4) 
Sclerodactyly, N (%) 1 (11.1) 1 (11.1) 
Sicca, N (%) 2 (22.2) 3 (33.3) 
Arthritis, N (%) 3 (33.3) 6 (66.6) 
Cutaneous rash, N (%) 4 (44.4) 5 (55.5) 
Raised CK/myositis, N (%) 2 (22.2) 2 (22.2) 
Leucopaenia, N (%) 2 (22.2) 3 (33.3) 
Thrombocytopaenia, N (%) 0  1 (11.1) 
Mouth ulcers, N (%) 1 (11.1) 2 (22.2) 
GORD, N (%) 0  1 (11.1) 
Telangiectasia, N (%) 1 (11.1) 1 (11.1) 
Photosensitivity, N (%) 0  3 (33.3) 
Table 18. CK, Creatinine kinase; GORD, Gastro-oesophageal reflux disease. 
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5.3.3 Treatment characteristics of the UCTD patients in this study 
Treatment characteristics of patients with UCTD (as agreed by Consultant diagnosis 
and the research investigator) and those who reclassified to CTD were compared. 
The proportions of patients on any concomitant immunosuppressant including 
glucocorticoids were similar between the two groups. However, the proportions on 
concomitant anti-malarials were higher in those who were re-classified to CTD 
compared to those whom UCTD diagnosis was agreed (Table 19).  
Following an assessment at the research clinic, treatment for those who were re-
classified as CTD was changed in 5/9 patients (2 were started on anti-malarials, 2 = 
Azathioprine and 1 = Intra-muscular glucocorticoids) as shown in Table 19.  
Table 19 Comparison of treatment characteristics between those whom a 
diagnosis of UCTD was agreed and reclassified to CTD 
Agent Agreed UCTD,  
N = 34 
Reclassified to 
CTD, N=9 
Any immunosuppressant including 
glucocorticoids, N (%) 
23 (67.6) 6 (66.7) 
Prednisolone, N (%) 2 (5.9) 0 
Anti-malarials, N (%) 13 (38.2) 5 (55.6) 
Methotrexate, N (%) 8 (23.5) 2 (22.2) 
Mycophenolate, N (%) 1 (2.9) 0 
Azathioprine, N (%) 3 (8.8) 0 
Sulfasalazine, N (%) 1 (2.9) 0 
Table 19. UCTD and reclassified CTD characteristic differences. 
 
5.3.4 IFN Scores were higher in those who re-classified to CTD than whom a 
diagnosis of UCTD was agreed 
Both IFN Scores (Score A and Score B) were compared between those whom a 
diagnosis of UCTD was agreed (n=34) and re-classified into CTD (n=9) following 
assessment at the research visit. IFN Score A was higher in the latter versus the 
former group (fold difference (FD) 2.76 (95% CI 1.11 - 6.88; p=0.030) (Figure 9-A). 
For IFN Score B, there was a trend to association for higher expression in those 
whom a diagnosis of UCTD was agreed versus classified to CTD (FD 1.74, 95% CI 
0.53 - 3.21; p=0.077) (Figure 9-B).  
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Figure 9 Comparison of IFN Scores between those who a diagnosis of UCTD 
was agreed and re-classified into CTD 
 
Figure 9. A) Mean gene expression of IFN Score A was higher in those whom a 
diagnosis of UCTD was agreed versus re-classified into CTD. B) There was a trend 
to higher mean gene expression in the latter versus former groups. Error bars 
denote upper and lower limits of the mean. CTD; connective tissue disease.  
5.3.5 Discussion 
In this chapter, a cohort of patients who had a Consultant diagnosis of UCTD were 
studied in order to phenotype those who had already met classification criteria of an 
established CTD (through schematic assessment of signs and symptoms against 
criteria) or remained “unwaveringly” undifferentiated. A substantial proportion of 
patients could be re-classified clinically, and this was supported by immunological 
evidence. These results show that the IFN Scores (i.e. particularly IFN Score A) can 
help to immunologically distinguish patients who may have a more severe disease, 
although we did not see evidence of this greater severity (e.g. in the form of greater 
therapy requirement) within this small cohort. 
UCTD is an understudied area in rheumatology and currently there is no widely-
accepted guideline on the management of this disease. The absence of universally-
accepted classification criteria for UCTD is a significant barrier for patient diagnosis 
and research. This was also acknowledged by the European Reference Network on 
Rare and Complex Connective Tissue and Musculoskeletal Diseases (ERN 
ReCONNET) group in their recent publication on UCTD[408]. The 1999 preliminary 
classification criteria for UCTD by Mosca et al.[114] could be used but might be 
perceived as outdated in light of the repeated revisions made to several of the 
classification criteria for definitive CTD since 1999. For instance, classification 
criteria for SLE has been revised twice i.e. in 2012[38] and 2018[409], while for pSS 
the criteria has been revised three times i.e. in 2002[68], 2012[410] and 2016[69]. 
Furthermore, some of these criteria were weighted to clinical significance and 
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clinicians often had to refer to the criteria glossary sections to learn how these 
criteria were scored. This can be time-consuming particularly in a busy clinic. Thus, 
the issues above motivated the exploration of the role of an IFN biomarker in 
delineating patients with definitive classifiable CTD from the undifferentiated.  
Recent advances have elucidated the important role of IFN in the pathogenesis of 
various CTDs[20, 411]. High expression of ISGs had been widely reported in both 
the tissues and serum of patients with SLE[24, 412, 413], pSS[414, 415], SSc[416, 
417] and IMs[418, 419]. Therefore, findings of higher ISG expression of patients with 
CTDs versus healthy controls are no longer perceived as novel, although may add 
to the wealth of the body of evidence. Studies pertaining the role of IFN-Is in UCTD 
have been limited. In one study by Wither et al., of the 28 patients with UCTD 
recruited, none of the patients at baseline with pre-SSc (Raynaud’s phenomenon, 
oesophageal dysmotility, telangiectasia and digital ulcers, in the absence of 
scleroderma or sclerodactyly) had high IFN-5 levels, whereas 50% of patients with 
incomplete lupus erythematosus (arthritis, lupus rashes, vasculitic skin lesions, 
pleuritis, idiopathic thrombocytopenic purpura, pericarditis and mucocutaneous 
ulcers) and 100% of patients with sicca symptoms and anti-Ro+ had high IFN-5 
levels. 23/28 patients had 1-year follow-up. Of these, 7/23 had progressed to 
meeting classification criteria of CTD at 1 year. However, there was no difference in 
baseline IFN-I5 levels between those who progressed to CTD versus those who 
remained undifferentiated[420]. It might be that IFN biomarkers were not predictive 
of progression from UCTD to CTD but these findings need to be interpreted with 
caution since the results could be influenced by the small sample size, short-term 
follow-up and potentially the performance of IFN signatures used (as discussed in 
Chapter 2.3.8).  
In this study, 9/43 (21%) were re-classified into CTD at the research visit following a 
schematic review of signs and symptoms against the four established criteria for 
SLE, pSS, SSc and IMs. The most common symptom for re-classification from the 
previous Consultant diagnosis was arthritis. The definition of arthritis based on the 
2012 SLICC criteria for SLE was synovitis involving two or more joints, 
characterised by swelling or effusion OR tenderness in two or more joints and thirty 
minutes or more of morning stiffness [38]. However, assessment of arthritis in the 
context of CTD can be challenging since patients often present with arthralgia but 
without obvious clinical synovitis. The use of musculoskeletal ultrasound has the 
potential to objectively assess this in CTD including SLE[421] but it still not used 
commonly in clinics compared to other inflammatory disease like RA. Hence this 
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could lead to discrepancy in the scoring of this element. Importantly, no discrepancy 
pertaining to major end organ involvement was observed between the two 
assessments. Although non-major organ threatening signs and symptoms such as 
leucopaenia, rash and photosensitivity could be overlooked in the previous 
Consultant diagnosis assessment, these did pose an impact on re-classification of 
patients to definitive classifiable CTD. This reclassification was supported by the use 
of novel two-factor for IFN status, as described in Chapter 3.2. IFN Score A which 
comprised many well-known ISGs that respond to IFN-I (IFN-α, -β -κ, -ω) was 
significantly higher in those who were reclassified to CTD compared to those 
remained undifferentiated. This elevated level was not affected by the use of 
concomitant DMARDs since more patients were on anti-malarials in the former 
group versus the latter group. Suppression of endosomal TLR activation by anti-
malarials has been attributed to the inhibition of endosomal acidification, which was 
a prerequisite for the activation of these receptors [422]. Although not statistically 
significant, there was a trend to increase in IFN Score B in the former versus latter 
groups. In contrast to IFN Score A, IFN Score-B comprised ISGs that coincided with 
M3.4 and M5.12 modules of a previous microarray study [376], which were 
suggested to be responsive to not only IFN-I but also IFN-II (IFN-γ), IFN-III (IFN-λ) 
as well as other inflammatory mediators which are yet to be discovered[423]. 
Moreover, following the research assessment, about half of the patients had their 
immunosuppressive therapies escalated.  
This study has some limitations. First, the two assessments of UCTD were not 
undertaken at the same time which could theoretically contribute to the discrepancy 
in classifying patients. However, all patients with UCTD were seen in the research 
clinic within 3 months i.e. median 4 weeks. Since these patients were deemed 
stable with no change in immunosuppressive therapies in the NHS clinic, the 
likelihood that these patients would have progressed to CTD was low. Second, 
although largest in this field to date, the sample size was low, which was also 
demonstrated by the wide confidence intervals in both IFN scores. Thirdly, the re-
definition of UCTD would be achievable through more stringent application of the 
classification criteria by clinicians. Lastly, the role of these IFN biomarkers in the 
prediction of progression to CTD could not be deduced in the absence of 
longitudinal follow-up. 
5.3.6 Conclusion 
In conclusion, the current proposed classification criteria for UCTD led to 
discordance in disease classification between a Consultant diagnosis in a routine 
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clinic and a schematic review against established classification criteria for SLE, pSS, 
SSc and IM. Patients who were classified to CTD based on the latter method of 
assessment were supported by the use of IFN assays i.e. IFN Score A. Longitudinal 
study of the use of IFN biomarkers in patients who are labelled as UCTD may help 
elucidate their use in prognostic stratification and identify those who may need 
greater immunosuppression for disease control.  
5.3.7 Key messages 
 In a cohort of patients labelled as UCTD under a Consultant diagnosis in clinic, 
9/43 (21%) were re-classified into CTD using a schematic review against 
established classification criteria for SLE, pSS, SSc and IM.  
 The discrepancy in both methods of disease classification was contributed to by 
a lack of a formal classification criteria for UCTD. 
 IFN Score A was higher in those who were re-classified into CTD than those 
remained undifferentiated, thus could be used to distinguish between these two 






















Chapter 6 Relationship between IFN activity and patient-reported outcomes 
among individuals at risk and with established CTD, including UCTD 
6.1 Introduction 
Connective tissue diseases (CTD) are chronic, systemic rheumatic diseases that 
have the potential to impose a significant impact on patients’ well-being and health-
related quality of life[35, 424]. Interferons (IFNs) are pro-inflammatory cytokines that 
play a pivotal role in the pathogenesis and activity of CTD[20, 425, 426]. IFN-I is 
systemically upregulated in a significant proportion of patients with CTD, and has 
been detected at higher levels of expression in patients at risk of CTD and with 
UCTD[20, 25, 427]. Multiple studies have described physician-reported associations 
between IFNs and the CTDs, such as correlations with disease flares and 
therapeutic response, however few studies have explored the relationship between 
IFN and patient-reported outcome measures (PROMs) in the CTDs[20, 426]. 
Fatigue is a major complaint in patients with CTD[428, 429]. The cause of fatigue is 
unclear, however likely multifactorial, originating including among others, the pro-
inflammatory state, depression, medication effects and medical co-morbidities[428-
430].The concept of higher levels of IFN leading to worse fatigue was researched by 
Howard-Trip et al. (2016) in a cohort of patients with pSS [431]. Remarkably, 
Howard-Tripp et al. found an inverse relationship between many pro-inflammatory 
cytokines and fatigue, which includes IFN-γ (p=0.022), and no significant 
relationship between IFN-α and fatigue[431]. These results support a more complex 
relationship in IFN and fatigue immunophysiology, and possibly one where the initial 
inflammatory response is driven by IFN, however followed by regulatory 
mechanisms comprised of other cytokines that are responsible for the sustained 
fatigue[431]. Alternatively, the study used a cytometric bead array immunoassay to 
measure cytokine expression. Prior work suggests that immunoassays are sensitive 
to the metabolic activities of cells in the blood and may misestimate the expression 
of IFN[25].  
The impact of therapeutic IFN when used as an anti-viral, immunomodulatory and 
antineoplastic therapy in conditions other than CTD may be extrapolated to 
understand the impact of IFN on patient’s quality of life. In a superiority study that 
compared IFN-containing versus non-IFN-containing regimens for chronic hepatitis 
C in elderly patients, IFN-free courses of therapy were found to have substantial 
superiority in PRO data compared to the IFN-containing regimens[432]. Physical 
functioning, vitality, physical and emotional well-being, fatigue levels, and activity 
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and energy were significantly decreased in patients who received IFN, which was 
seen to resolve within 4 weeks after treatment cessation[432]. Superiority in health-
related quality of life has been reported in other studies comparing IFN-free and 
IFN-containing regimens, including in treatment programs for Hepatitis C, multiple 
sclerosis and renal cell carcinoma[432-436]. Collectively, this data suggests that IFN 
has a direct impact on quality of life.            
Patient reported outcomes (PROs) reflect patients’ perspectives on their illness, 
health-related quality of life, and well-being, and can be used in screening, 
monitoring, or evaluating interventions or to stimulate dialogue between patient and 
clinician[377]. Evidence suggests that patient-reported symptoms have greater 
importance on health-related quality of life than disease manifestations captured on 
physician indices[437, 438]. However, to date, there are limited data pertaining to 
comparison of PROMs between disease subgroups. Our group (for which I am a co-
author) had evaluated the use of patients’ VAS score of global health assessment of 
disease activity in pre-CTD or so called “At-Risk” group[25]. Although this was not 
independently predictive of progression to CTD in multivariable analysis, there was 
a trend to increase in VAS score at baseline in those who progressed versus those 
who remained At-Risk in univariable analyses. Hence, the scores of PROMs in this 
group could be important. Lastly, studies on the use of PROMs in UCTD are lacking. 
Therefore, it would be interesting to compare PROMs between these three disease 
subgroups to evaluate their relationship to a known biomarker of disease activity, 
namely IFN-I. 
6.1.1 Hypothesis 
i. Patient-reported outcomes correlate with IFN Score A and IFN Score B in 
patients with CTD, UCTD and who are At-Risk of CTD 
6.1.2 Objectives 
i. To determine whether IFN Score A and IFN Score B correlate with patient-
reported outcomes in CTD, UCTD and patients At-Risk of CTD 
6.2 Methods 
6.2.1 Design and Patient 
A cross-sectional study of consecutive three groups of patients: (i) Group 1: CTD; (ii) 
Group 2: UCTD and (iii) Group 3: At-Risk of CTD was conducted at a single centre 
in Leeds between July 2017 till March 2019.  
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Inclusion criteria were (i) adults between 18-80 years; (ii) Group 1 (CTD): fulfilling 
classification criteria for an established CTD[38, 71, 80, 405, 439] including anti-
neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)[440]; or Group 
2 (UCTD): ANA positive; signs and symptoms suggestive of CTD but not fulfilling 
classification criteria for an established CTD[38, 71, 80, 405] or RA[407]; disease 
duration of at least 12 months and UCTD diagnosis was made by Consultant 
Rheumatologists; or Group 3 (At-Risk of CTD): ANA positive, ≤1 clinical criterion 
based on SLICC-12 for SLE[38] and not meeting classification criteria for other 
CTDs[69, 80, 441] or RA[442]; (3) symptom duration <12 months; (4) glucocorticoid, 
anti-malarial and immunosuppressive treatment-naïve. 
6.2.2 Ethical approval 
All individuals provided informed written consent and this research was undertaken 
in compliance with the Declaration of Helsinki (Chapter 9). The patients’ blood 
samples used for this study were collected under ethical approval, REC approval 
17/YH/0166, National Research Ethics Committee Yorkshire and the Humber – 
South Yorkshire. All experiments were performed in accordance with the relevant 
guidelines and regulations. The University of Leeds was contracted with 
administrative sponsorship. 
6.2.3 Clinical data 
At a single research visit, a comprehensive clinical assessments were conducted. 
Data collection included age, gender, ethnicity, history of first or second degree 
relative(s) with rheumatic and musculoskeletal diseases (RMDs), smoking history, 
presence of fibromyalgia, treatment including DMARDs and corticosteroids. Active 
disease was defined according to the impression of the evaluating clinician.  
6.2.4 Patient-reported outcome measures (PROMs) 
At the study visit, the following PROMs were administered to participants for 
completion on the day of the visit: VAS pain, VAS morning joint stiffness, VAS 
arthritis, VAS fatigue, VAS global health, RAND® 36-Item Health Survey version 1.0 
(SF-36), 5-level EQ-5D (EQ-5D-5L), Work Productivity and Activity Impairment 
questionnaire: Specific Health Problem version 2.0 (WPAI:SHP), ICEpop CAPability 
measure for Adults (ICECAP-A), and the Functional Assessment of Chronic Illness 
Therapy - Fatigue Scale (FACIT-Fatigue) version 4. Details of these PROMs are 
summarised in Chapter 3.4.  
6.2.5 Laboratory and IFN assays 
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ANA was tested using immunofluorescence and a panel of nuclear autoantibodies 
including anti-dsDNA, extractable nuclear antigens (ENA, including Ro52, Ro60, La, 
Sm, Chromatin, RNP, Ribosomal P, Jo-1, Centromere and Scl-70) using the Bioplex 
2200 Immunoassay.  
Samples for IFN biomarkers were collected and processed as per Chapter 3.2. IFN 
Score A and IFN Score B were calculated without the knowledge of the participants’ 
clinical status. 
6.2.6 Statistical analyses 
Descriptive statistics were summarised using mean with standard deviation or 
median with interquartile range for continuous variables (where appropriate) and 
proportion for categorical variables. Associations between categorical variables 
were tested by Chi-squared test while for continuous variables, either Student’s t-
test or ANOVA followed by pairwise Tukey tests. Correlation between two 
continuous variables was tested using Spearman’s correlation coefficient. 
 
Due to the scope of this thesis as an MSc, it is not possible for me to analyse risk 
factors for all the PROMs above individually. Therefore, since fatigue and patients’ 
perception of their global health were considered to be the most impactful to the 
patients, risk factors for the two PROMs, FACIT-Fatigue and EQ-VAS were 
evaluated. Some of the clinical data were missing. Imputation by predicted mean 
matching was used to estimate these missing data since frequency of missing data 
were less than 5%. For prediction of FACIT-Fatigue and EQ-VAS, initially 
univariable analyses using linear regression were performed on each of the 
plausible predictors. Then after, multivariable analyses were performed using linear 
regression with backwards elimination with a p-value of <0.25 as a criterion for 
exclusion from the model.  
6.3 Results 
6.3.1 Patient characteristics 
A total of 279 patients were recruited into the study. Of these, 127 patients had a 
diagnosis of CTD or Vasculitis, 42 UCTD and 110 At-Risk of CTD. The most 
common subtype of established CTD was SLE (61.4%) followed by pSS (16.5%), 
EGPA (6.3%), anti-synthetase syndrome (5.5%), MCTD (4.7%), SSc (4.7%), and 
APLS (0.8%). 
The mean age of patients for CTD and Vasculitis, UCTD and At-Risk of CTD groups 
were 48.6, 49.8 and 50.6 years respectively. The majority of patients were female, 
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White and had one ANA specificity. Approximately one in ten patients were smokers 
or had symptoms of fibromyalgia. Over one third of patients in the CTD group had 
internal organ involvement  compared with 11.9% in the UCTD group and none in 
the At-Risk group. In most cases, the involvement was limited to only one internal 
organ i.e. nephritis. Active disease at research assessment was detected in 70.9% 
of the CTD group and 76.2% of the UCTD group. This corresponded with a modest 
rate of prednisolone use at 36.2% and 7.1% of the CTD and UCTD groups 
respectively. Baseline clinical and demographic characteristics are presented in 
Table 20. 





At-Risk of CTD 
N=110 
Age, mean (range) 48.6 (21, 88) 49.8 (22, 72) 50.6 (18, 89) 
Female : Male 107 : 20 35 : 7 94 : 16 
White ethnicity 76 (59.8%) 31 (75.6%) 76 (69.1%) 
Total ANA specificities 
One 
Two  

















Internal organ involvement 59 (46.5%) 5 (11.9%) 0 (0%) 
Number of internal organs  
One 










Fibromyalgia 14 (11%) 5 (11.9%) 9 (8.2%) 
Prednisolone use  46 (36.2%) 3 (7.1%) 0 (0%) 
csDMARD(s) 101 (79.5%) 28 (66.7%) 3* (2.7%) 
Smoker 17 (13.4%) 8 (19%) 10 (9.1%) 





















Table 20. Patient characteristics. APLS, Anti-phospholipid syndrome; EGPA, 
Eosinophilic granulomatosis with polyangiitis; IIF: Indirect ANA immunofluorescence. 
*csDMARDs prescribed for non-rheumatic disease e.g. psoriasis or Crohn’s colitis.  
6.3.2 Completion of PROMs 
Across the groups, approximately one in five patients failed to complete the PROM 
assessments in full (Table 22). The highest completion rate was seen for the VAS 
PROMs at approximately 1 in 9 patients. The WPAI:SHP (35.4% CTD; 35.7% 
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UCTD; 34.5% At-Risk) and VAS arthritis (38.6% CTD) were the PROMs with the 
lowest frequencies of full completion. 
Table 21 Full completion rates of PROMs (sub-grouped) 
PROM Instrument CTD UCTD At-Risk of 
CTD 
VAS pain 
VAS morning joint stiffness 
VAS arthritis 
VAS fatigue 








































Table 21. Completion rates of the PROMs according to subgroup. 
6.3.3 Comparison of PROMs between disease subgroup 
In general, there are no consistent differences in the various PROMs used between 
disease subgroup. The PROMs with differences are described in detailed below. 
VAS scores were measured in 10cm scale. For VAS morning joint stiffness (EMS), 
there was a difference between groups, ANOVA F=3.21; p=0.043. Within groups, 
the only difference was that patients with UCTD had higher VAS-EMS score than At-
Risk group; mean difference 1.50 (95% CI 0.10 t0 2.90); p=0.033. 
For the General Health item of the SF-36 score, there was a difference between 
groups, ANOVA F=6.15; p=0.002. Within groups, the only difference was that 
patients with At-Risk had higher SF-36 General Health scores than the established 
CTD & Vasculitis group (i.e. the higher the item score the better the perception of 
general health); mean difference 10.69 (95% CI 3.47 to 17.93); p=0.002. 
For the FACIT-Fatigue score (ranges between 0-52), the higher the score, the less 
fatigue reported by the patients. There was a difference between groups, ANOVA 
F=4.08; p=0.018. Within groups, patients with At-Risk had higher FACIT-Fatigue 
score than the established CTD & Vasculitis group; mean difference 5.44 (95% CI 
0.74 to 10.13); p=0.019. 
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6.3.4 IFN status between the groups 
IFN Score A differed between the groups (ANOVA F=42.31; p<0.001). The gene 
expression was higher in the CTD and Vasculitis in relation to the At-Risk groups; 
fold difference (FD) 1.78 (95% CI 1.07 to 2.47); p=0.001. There were no differences 
in gene expression between CTD and Vasculitis and UCTD groups; p=0.111 and At-
Risk and UCTD; p=0.735 (Figure 10-A).  
In contrast, there was no difference in IFN Score B between the groups overall 
(ANOVA F=0.986; p=0.652) (Figure 10-B).  
Figure 10 Comparison of IFN scores between patients with CTD & Vasculitis, 
UCTD and At-Risk 
 
Figure 10. Graph A) IFN Score A differed between groups. There was a higher 
expression of IFN Score A in CTD & Vasculitis in relation to At-Risk groups. Graph 
B) IFN Score B did not differ between groups. Error bars denote upper and lower 
limit of the mean. AI-CTD; autoimmune connective tissue disease. 
6.3.5 Correlations between PROMs and IFN scores between the groups 
Correlations between PROM scores and IFN scores were performed in observed 
data using reflected delta Ct (ΔCt) so that higher scores represented greater 
expression for the latter. In general, there was no consistent correlation between 
IFN scores and the various PROMs evaluated in this study based on disease 
subgroups. Only variables with that were correlated with IFN scores are described 
below.  
In the UCTD group, there were moderate correlations between IFN Score A and SF-
36 Energy Function (n=36, Spearman’s r=0.353, p=0.034), IFN Score A and SF-36 
Emotional well-being (n=36, Spearman’s r=0.394, p=0.017), IFN Score A and SF-36 
Social Functioning (n=36, Spearman’s r=0.337, p=0.044), and IFN Score A and 
ICECAP (n=34, Spearman’s r=0.370, p=0.031). and IFN Score A and EQ-VAS 
(n=34, Spearman’s r=0.363, p=0.035). Next, there were also moderate correlations 
between both IFN scores and the SF-36 General health and well-being; IFN Score A 
94 
 
(n=37, Spearman’s r=0.397, p=0.015) and IFN Score B (n=37, Spearman’s r=0.399, 
p=0.014) respectively.  
In the At-Risk group, IFN Score B was weakly correlated the WPAI:SH percent 
activity impairment scores (n=62, Spearman’s r=0.269, p=0.035).Patients who had 
impairment in the EQ-5D-5L Self-care scores had higher IFN Score B expression 
compared to those without impairment; FD 0.74 (95% CI  0.55 to 0.92); p=0.044.   
In the established CTD and Vasculitis group, IFN Score A was only weakly 
correlated with VAS Arthritis (n=51, Spearman’s r=-0.330, p=0.028) and SF-36 
physical functioning scores (n=112, Spearman’s r=0.208, p=0.028).   
6.3.6 Multivariable analysis of predictors of FACIT-FATIGUE 
FACIT-Fatigue scores are inversely representative of the level of fatigue i.e. the 
higher the score, the less fatigue and better quality of life reported by the patients. In 
imputed univariable analyses, putative predictors that were associated with worse 
(i.e. lower) FACIT-Fatigue scores were female, presence of fibromyalgia, 
concomitant DMARDs, current smoker, current features of active disease and 
disease subgroups. Older age was associated with better (i.e. higher) FACIT-
Fatigue score.  
In multivariable analysis, predictors of worse (lower) FACIT-Fatigue scores were 
female, presence of fibromyalgia, current smoker and current features of active 
disease. Older age and higher IFN Score A expression was associated with better 
(higher) FACIT-Fatigue score (Table 22). 
Table 22 Linear regression for predictors of FACIT-FATIGUE score 
Baseline predictors Univariable UCEB (95% CI), 
p value 
Multivariable UCEB (95% CI) 
p value 
Age 0.154 (0.03, 0.27), 0.010 0.132 (0.01, 0.24), 0.022 
Female -6.386 (-11.41, -1.36), 0.013 -5.790 (-10.5, -1.06), 0.017 
White ethnicity 2.322 (-1.76, 6.41), 0.265 Excluded 
Internal organ 
involvement 
0.406 (-3.85, 4.66), 0.851 Excluded 
No. of ANA-
specificities 
-0.372 (-2.00, 1.26), 0.655   Excluded 
Fibromyalgia  -14.600 (-20.05, -9.14), <0.001 -10.873 (-16.38, -5.35), <0.001 
Prednisolone  -4.182 (-9.07, 0.713), 0.094 -2.791 (-7.31, 1.73), 0.225 
csDMARD use  -4.162 (-7.78, -0.53), 0.025 Excluded 
Current smoker -9.243 (-14.19, -4.29), <0.001 -5.602 (-10.34, -0.86). 0.021 
Active disease -7.759 (-11.30, -4.21), <0.001 -6.996 (-10.55, -3.44), <0.001 
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Table 22. FACIT-Fatigue. *Analysis was based on reflected ΔCt . Higher values 
indicate higher gene expression to give positive values for UCEB. UCEB, 
unstandardized co-efficient B.  
6.3.7 Multivariable analyses of predictors of EQ-VAS 
EQ-VAS scores were scored on a 100mm scale and are related to the patients’ 
subjective perception of their health state  i.e. the higher the score, the better they 
felt about their health. In imputed univariable analyses, putative predictors that were 
associated with lower (worse) EQ-VAS scores were female, presence of 
fibromyalgia, concomitant prednisolone, concomitant DMARDs, current smoker and 
current features of active disease.   
In multivariable analysis, predictors of lower (worse) EQ-VAS scores were female, 
presence of fibromyalgia, current features of active disease and higher IFN Score B. 
Higher IFN Score A was associated with higher (better) EQ-VAS scores (Table 23).   
Table 23 Linear regression for predictors of EQ-VAS 
IFN Score A (-ΔCt) 0.074 (-0.997, 1.145), 0.891 1.598 (0.325, 2.872), 0.014 
IFN Score B (-ΔCt) -0.877 (-2.615, 0.860), 0.321 -1.878 (-3.786, 0.031), 0.054 
At-Risk v UCTD v CTD  -2.68 (-4.64, -0.72), 0.008 Excluded 
Baseline 
predictors 
Univariable UCEB (95% CI), 
p value 
Multivariable UCEB (95% CI), 
p value 
Age 0.980 (-0.09, 0.27), 0.304 Excluded 
Female -8.041 (-16.08, -0.00), 0.050 -8.503 ( -16.40, -0.60), 0.035 
White ethnicity  4.350 (-2.08, 10.78), 0.185  3.674 ( -2.79, 10.14), 0.264 
Internal organ 
involvement 
 -4.850 (-11.62, 1.92), 0.160 Excluded 
No. of positive 
ANA-specificities 
 -0.041 (-2.64, 2.56), 0.975 Excluded 
Fibromyalgia -20.770 (-29.53, -11.89), 
<0.001 
 -16.829 (-26.10, -7.54), <0.001 
Prednisolone use -10.84 (-18.64, -3.04), 0.007  -10.503 (-18.66, -2.33), 0.012 
DMARD use -7.009 (-12.67, -1.33), 0.016 Excluded 
Current smoker -4.580 (-12.66, 3.49), 0.265 Excluded 
Active disease -9.680 (-15.32, -4.03), 0.001  -10.353 (-17.74, -2.96), 0.006 
IFN Score A (-ΔCt) 0.628 (-1.064, 2.320), 0.465  2.757 (0.533, 4.754), 0.014 
IFN Score B (-ΔCt) -1.183 (-3.979, 1.614), 0.406  -3.374 (-6.608, -0.140), 0.041 
At-Risk v UCTD v 
established CTD  
-2.814 (-5.86, 0.24), 0.071  1.604 (-2.54, 5.74), 0.446 
96 
 
Table 23. EQ-VAS. *Analysis was made based on reflected ΔCt . Higher values 
indicate higher gene expression to give positive values for UCEB. UCEB, 
unstandardized co-efficient B.  
6.4 Discussion 
In this study, no consistent relationship was found between the IFN Scores and 
various PROMs. However in a subgroup of patients with UCTD, IFN Score A was 
moderately correlated with components of the SF-36, the ICECAP-A and the EQ-
VAS. In At-Risk individuals, weak correlations were detected between IFN Score B 
and WPAI:SH percent activity impairment scores and EQ-5D-5L self-care scores. In 
CTD and Vasculitis patients, the only association found was a weak correlation 
between IFN Score A and VAS arthritis and the SF-36 physical function. Therefore, 
it appears that IFN Scores may be unreliably correlated with PROMs. However, 
when these assays were included with other clinical variables, IFN Score B was 
independently predictive of worse patient perception of health based on EQ-VAS. In 
contrast, higher IFN Score A was independently predictive of lower fatigue based on 
FACIT-Fatigue and better patient perception of health based on EQ-VAS.  
This was the first study that compared PROMs between patients with CTD and 
Vasculitis, UCTD and At-Risk. As expected, patients with CTD and Vasculitis had 
lower FACIT-Fatigue scores (i.e. more fatigue) compared to individuals At-Risk. 
Moreover, patients within the CTD and Vasculitis subgroup had worse perception of 
health based on lower SF-36 General health scores than individuals At-Risk. This 
agreement could be representative of the burden of disease in established CTD. 
In this study, IFN Score A was moderately correlated with a number PROMs in the 
UCTD group compared to established CTD and At-Risk individuals. The observation 
that an immunological abnormality could correlate with a patient’s perception of 
health in this cohort is intriguing. Therefore this study highlights that there are 
various unanswered questions in the field of UCTD research in relation to the 
relationship between disease features, immunological disturbances and PROMs, 
which could be the focus of future research. 
In a previous study by Howard-Tripp and colleagues, they found an inverse 
relationship between IFN-γ and fatigue in pSS, while IFN-α demonstrated no 
significant relationship[431]. However our findings differed with this in that the higher 
the expression of IFN Score A (i.e. comprised of ISGs that were responsive to IFN-
I), the lower the level of fatigue, and the better the EQ-VAS scores as reported by 
patients. Furthermore I also found that higher IFN Score B was predictive of worse 
patient perception of general health score as based on EQ-VAS. One potential 
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explanation for these observations could be that IFN-I might have a short-lived role 
in early onset of fatigue, whereas in chronic fatigue this could be mediated by other 
different cytokines other than IFN[431]. Indeed, as described in Chapter 3 and 
Chapter 5, IFN Score B comprised a set of ISGs which were mostly responsive to 
IFN-I, IFN-III and other inflammatory cytokines which have yet to be determined. 
Another explanation of the observed relationship between IFN and PROMs could be 
the failure to return to baseline levels of health following active disease. With 
regards to the inverse relationship between IFN-γ and fatigue, I was not able to 
confirm this as reported by Howard-Tripp et al. as IFN-γ is a IFN-II which was not 
evaluated in my study.  
The limitations of this study is that not all PROMs were completed by participants. 
However our incompletion rate was still lower compared to other studies using 
PROMs, which ranged between 0.3% - 96.4%[434, 436, 443]. Secondly, 
psychosocial factors beyond immunological processes may have influenced 
participant responses to the PROMs (i.e. depression). Lastly, since this study was 
exploratory, various PROMs were administered to participants since it was not 
known which one was predominant. Hence the collection of questionnaires was 
quite arduous to patients and could have influenced responses.  
6.5 Conclusion 
In conclusion, in this exploratory study, we have demonstrated moderate correlation 
between IFN Score A and several PROMs in UCTD, but an inconsistent relationship 
between PROMs and At-Risk and established CTD. Our data also suggests that the 
relationship between IFN activity and PROM was not straightforward, and that other 
clinical risk factors and potentially other cytokines should be taken into account with 
respect to PROMs. These findings may be relevant to the subgrouping and 
assessment of patients for therapy targeting the IFN system.            
6.6 Key messages 
 Correlation between IFN Scores and PROMs varied widely among 
diagnoses of CTDs, with the strongest correlation found in patients with 
UCTD. 
 Higher IFN Score B was independently predictive of poor perception of 
general health based on EQ-VAS. 
 The relationship between IFN activity and PROM is not straightforward, and 
other clinical risk factors and potentially other cytokines should be taken into 
account with respect to PROMs.  
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Chapter 7 Discussion 
7.1 General discussion of results 
The data presented in this thesis highlights the potential applications of an IFN 
assay in the diagnosis and management of patients with CTD. Given the 
heterogeneity in the genetics, aetiopathogenesis and clinical phenotype of these 
conditions, it is likely that an IFN assay will not have universal application as a 
biomarker for prognostic, diagnostic, predictive or surrogate purposes in all 
individuals within the CTD spectrum. This programme of research was designed to 
explore the potential applications for an IFN assay such that clinical goals could be 
achieved for the purpose of improved outcomes for patients with CTD. The 
programme was focussed on three key clinical areas: (i) the prediction of flares and 
glucocorticoid requirements in patients with SLE; (ii) the use of IFN assays in 
distinguishing patients with classifiable CTD immunologically from a cohort of 
patients labelled as UCTD; and (iii) the relationship of the IFN assays with PROMs 
in patients At-Risk, with UCTD and with established CTD. By distinguishing the 
association of the IFN assays in the identification of classifiable CTD from a cohort 
of patients initially labelled as UCTD; the predictive ability of the IFN assays to 
identify flares and glucocorticoid requirements in patients with SLE; and the 
relationship between IFN assays and PROMs across the range of CTD diagnoses, 
the unifying hypothesis of this thesis which was that the use of interferon biomarkers 
will aid the prognosis and management of autoimmune connective tissue diseases  
has been addressed.  
Disease identification, prognosis and prevention is often a focus of research and 
management in rheumatology. However this will continue to operate with uncertainty 
while the immunopathogenesis of CTD is poorly understood and when reliable 
prognostic, diagnostic, predictive and surrogate biomarkers remain unidentified[18]. 
IFNs are essential mediators of autoimmunity but their role is poorly defined. This 
could be due to variability in pathogenic mechanisms among individuals with 
autoimmunity, different time points in pathogenic action of IFN within patients and 
diseases, or variation in sensitivity and specificity of methods for quantifying IFN 
status and activity. Previous work in this area has sought to improve methods of IFN 
quantification. Earlier publications from our institution have reported work on two 
continuous ISG expression scores (IFN Score A and IFN Score B) and a flow 
cytometric cell specific marker memory B cell tetherin[24, 373]. The ISG expression 
scores have been shown in combination to be better at identifying clinically 
meaningful differences in IFN status within a range of autoimmune rheumatic 
diseases[25]. This includes prediction of progression to CTD in an At-Risk 
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population and disease severity and activity in an SLE cohort [24, 352]. Memory B 
cell tetherin levels have been shown to be related to SLE diagnosis, disease 
severity and flares [352, 373]. Through examination of the performance of these IFN 
assays in other clinical scenarios, as I have shown, we find that (1) IFN Score A, 
IFN Score B and memory B cell tetherin may be predictive of future flare and 
glucocorticoid requirements in an SLE population; (2) that IFN Score A and Score B 
may identify patients who are eligible for re-classification into established CTD after 
an initial diagnosis of UCTD; and lastly (3) that IFN Score A has moderate 
correlation with several PROMs in UCTD, but an inconsistent relationship between 
PROMs and At-Risk and established CTD. These results have confirmed the 
importance of IFN in the disease activity and impact of CTD. The findings have the 
power to inform future research in IFN and the understanding of its role in 
autoimmunity.  
The inconsistent relationship between the IFN Scores and various PROMs was an 
intriguing finding in this work. As explained, PROM results may be influenced by 
other clinical risk factors and potentially other cytokines, as well as the failure of the 
patient to return to baseline levels of health following active disease. Future clinical 
studies may therefore be better positioned to examine the relationship between IFN 
and PROMs through prospective methodology, instead of relying on cross-sectional 
sampling. Exploratory studies on the cytokine milieu during different phases of CTD 
development could also be of value to broaden our understanding of CTD disease 
pathogenesis. Composite biomarker panels are an option if heterogeneity in 
cytokine activity is found across the CTD spectrum.  
7.2 Impact of research 
This programme of research has importance from an international perspective in 
terms of improving the diagnosis and management of CTD. It has explored specific 
clinical applications for IFN score A, IFN Score B and memory B cell tetherin, and 
although validation studies are required before recommendations can be drawn, 
these studies support the candidacy of these three IFN assays as future predictive 
and prognostic biomarkers in CTD. This research also affirms the central role of IFN 
in disease pathogenesis in CTD. The lack of strong correlation between IFN and 
multiple PROMs informs future studies that may use these tools as activity or 
response measures. 
7.3 Future perspectives 
The available data clearly demonstrate that there is a potential for the three IFN 
assays to be biomarkers in the prediction and prognosis of clinical aspects of CTD. 
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However in some patients, the scores were not predictive or prognostic and this is 
likely due to heterogeneity in cytokine activity between and within individuals and 
disease subtypes. Although the results are promising, the studies in this body of 
work were small and not powered or designed as validation studies. In terms of this, 
a validation study on the prognostic ability of the scores is currently in progress. The 
Defining Interferon in autoimmune Connective Tissue Diseases study (DEFINITION) 
is a powered, longitudinal study that will examine the parameters tested in this work 
over multiple time points and in cases of At-Risk, UCTD and established CTD. At 
the time of writing, the study had recruited 333 participants and is expected to 
release a preliminary report in 2020.   
7.4 Conclusions 
Three IFN assays were examined with respect to three clinical scenarios in this 
program of work. IFN Score A, IFN Score B and memory B cell tetherin was found to 
be significantly associated with activity and glucocorticoid requirements in SLE. IFN 
Score A and Score B was detected to identify patients who were eligible for re-
classification into established CTD after an initial diagnosis of UCTD. Correlation 
between IFN Scores and PROMs varied widely among diagnoses of CTDs, with the 
strongest correlation found in patients with UCTD. These findings together suggest 
that there may be a role for IFN assays in the prognosis and management of CTDs. 
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